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Abstract 
 
Inorganic phosphate (Pi) is an essential element that fuels vital processes in the body.  
To date, there is discord regarding the mechanisms of Pi regulation and the proportion 
of transport attributed to active (sodium-driven), paracellular, or uncharacterized 
transcellular pathways. The present studies address this by comparing Pi transport in 
different segments of the intestine using in vitro, in situ, and ex vivo techniques.  
Potential Pi signalling between the intestine, kidney, and liver was also investigated 
using intestinal perfusion and in vivo renal clearance surgeries.   
 
Regional differences in intestinal Pi transport were investigated using the in situ closed-
loop, in vitro everted sleeve, and ex vivo intestinal perfusion techniques.  These studies 
highlighted measured Pi transport discrepancies between methods, confirmed the 
jejunum as the site of highest Pi transport ability in the GI tract, and also revealed that 
the distal colon transported a significant amount of Pi both in vitro and in situ.  An 
intestinal perfusion technique never applied to studies of Pi transport also exposed a 
concentrated amount of Pi transported directly across the rat intestinal epithelium.  
 
Renal Pi clearance surgeries investigated a proposed Pi sensing mechanism between 
the small intestine and the kidney in which a high duodenal Pi load triggered rapid 
phosphaturia.  Present data show no phosphaturia after a physiological 10mM Pi 
duodenal instillation.  In contrast with previously published data, a high Pi load into the 
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duodenum increased plasma Pi and parathyroid hormone (PTH) levels resulting in 
correlated phosphaturia.  
 
The role of the liver in Pi transport was investigated by removing the liver following 
instillation of 1, 5, 10, and 15mM 32P coupled Pi buffer into the jejunum.  Data show a 
steady increase of Pi accumulated in the liver, which correlated with increased Pi 
concentration instilled into the jejunum.  Between 10 and 15mM however, the Pi in the 
liver reached saturation, suggesting that the liver may only store physiological 
concentrations of Pi.  Sodium-dependency of Pi uptake by the liver was also not 
apparent until 15mM Pi, in contrast with sodium-dependent Pi transport by the intestine 
at all four concentrations.  This finding suggests a separate mechanism of liver Pi 
transport at this supraphysiological Pi concentration.   
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ABBREVIATIONS, ACRONYMS, and ALTERNATE NAMES 
 
ADHR -------------------- Autosomal dominant hypophosphataemic rickets 
ASARM ------------------ Acidic serine-aspartate-rich MEPE-associated motif 
ATP ----------------------- Adenosine triphosphate 
BBM ---------------------- Brush border membrane 
BLM ----------------------- Basolateral membrane 
cAMP ----------- ---------- Cyclic adenosine monophosphate 
Calcifediol--------------- 25-hydroxyvitamin D3 (unhydroxylated vitamin D) 
Cholecalciferol---------7-Dehydrocholesterol (unhydroxylated calcifediol) 
CaSR --------------------- Calcium-sensing receptor 
CKD ----------------------- Chronic kidney disease 
EGF ----------------------- Epidermal growth factor 
EM ------------------------- Electron microscopy 
FGF-23 ------------------- Fibroblast growth factor – 23 
FGF-7--------------------- Fibroblast growth factor – 7 
GFR ----------------------- Glomerular filtration rate 
HHRH -------------------- Hereditary hypophosphatemic rickets with hypercalciuria 
HPO42- -------------------- Divalent phosphate anion 
HPO4----------------------- Monovalent phosphate anion 
IP -------------------------- Intraperitoneal 
IV--------------------------- Intravenous 
KO ------------------------- Knock out (mouse) 
LXR ----------------------- Liver X receptor 
MAP----------------------- Mean arterial (blood) pressure 
min------------------------- Minutes 
NAD ----------------------- Nicotinamide adenine dinucleotide 
NaPi ---------------------- Sodium phosphate cotransporter 
Pi -------------------------- Inorganic phosphate 
PFA ----------------------- Phosphonoformic acid
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PTH ----------------------- Parathyroid hormone 
SD ------------------------- Sprague dawley (rat) 
sFRP-4 ------------------- Secreted frazzle-related protein – 4 
TJ-------------------------- Tight junction 
TMD ----------------------- Transmembrane domain 
TIO ------------------------ Tumor-induced osteomalacia  
VDR ----------------------- Vitamin D receptor 
Vitamin D --------------- 1, 25 dihydroxyvitamin D3, (active vitamin D) 
VSMC -------------------- Vascular smooth muscle cells 
XLH ----------------------- X-linked hypophosphatemia
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Introduction to the physiological 
importance of phosphate and its regulation 
 
Phosphate is an important element that is required for vital pathways necessary to 
sustain life, pathways which include DNA regeneration, bone formation, and energy 
currency in the form of adenosine triphosphate (ATP). Phosphate is mostly obtained 
through the diet, and the regulation from the postprandial state to excretion is tightly 
maintained through a complex network of transporters and endocrine factors.  Shedding 
light on the links between dietary phosphate and the functions of these circulating 
factors in the small intestine, kidney, and potentially the liver, is particularly important in 
the context of chronic kidney disease (CKD), as phosphate homeostasis is disturbed 
and can lead to conditions exhibiting a high mortality rate. 
 
1.1 Physiological phosphate homeostasis 
Inorganic phosphate (Pi) is the form of phosphate obtained from the diet and differs 
from the organic compound found in nucleic acids, bioactive signaling proteins and cell 
membranes [1-3].   Pi is regulated according to the amount consumed, with male adult 
humans ingesting and storing a slightly higher amount than women [4].  As food enters 
the small intestine, Pi is absorbed in the duodenum and jejunum and transported to the 
extracellular fluid where it is then freely filtered by the kidney.  Approximately 70% of 
ingested Pi is absorbed in the small intestine, which constitutes more than what is 
biologically required [5].  Following that, about 80% of the Pi in the blood is reabsorbed 
by the kidney proximal tubules [6].  Skeletal Pi requirements involve roughly 70-80% of 
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total Pi in the blood, with Pi contained and stored in the bone and a small amount of Pi 
making a steady and equal Pi exchange with the extracellular fluid as needed [7]. The 
main concept in this homeostasis model is that excreted Pi via feces and urine is 
approximately equivalent to the amount ingested by the individual – this mechanism is 
essential in maintaining Pi balance (Figure 1.1).  
 
 
Figure 1.1.  Distribution of Pi in the human body from dietary source to excretion (adapted from 
[7]) 
The amount of Pi excreted via stool and urine is equivalent to the amount of Pi ingested, while there is 
an equal and constant exchange of Pi between extracellular stores and the bone.   
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1.2. Active Pi transport 
 
1.2.1 Sodium phosphate cotransporters – Type II (NaPis) 
The type II sodium-dependent phosphate cotransporters, part of the solute carrier family 
(SLC34), are the main Pi handlers in the body and are expressed primarily in the small 
intestine and the kidney.  Their expression at the brush border membrane (BBM) of 
intestinal enterocytes (NaPi-IIb) and renal proximal tubules (NaPi-IIa and IIc) is the rate 
limiting step for Pi transport [8, 9].    
 
1.2.1.1 NaPi distribution and protein expression 
NaPi-IIa is expressed in the S1-S3 [10] segments of kidney proximal tubules (highest in 
S1), while NaPi-IIc is confined to the S1 region  [11].  NaPi-IIa and NaPi-IIc are 
expressed on the BBM of the kidney proximal tubule across all species; however, 
segmental distribution of NaPi-IIb in the small intestine is species-specific.  In mice the 
highest expression occurs on the BBM of the ileum whereas in rats and humans, NaPi-
IIb expression and the majority of Pi transport takes place in the jejunum [12].  This 
difference in intestinal Pi handling is one of the main reasons behind using rat models 
when performing in vivo experiments relating to Pi uptake and regulation, as rats serve 
to be more physiologically relevant to humans.  More recently, NaPi-IIb has been shown 
to be expressed in the liver, supplementing previous studies showing that the only other 
tissue specific expression for the protein was the lung [13, 14].  The original proposed 
role of NaPi-IIb in the lung was to transport Pi to alveolar epithelial type II cells for 
surfactant synthesis which is important for lung function [15].   
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Expression of intestinal NaPi-IIb and renal NaPi-IIc decreases with age while renal 
NaPi-IIa expression seems to remain stable throughout life [16, 17].  This age-related 
decrease in expression of NaPi-IIb has been attributed to fact that Pi absorption from 
the diet/maternal circulation is essential during early development to promote skeletal 
growth [16].  Indeed the crucial role of intestinal NaPi-IIb in embryonic development has 
been shown by the phenotype of a targeted deletion mouse NaPi-IIb-/- model, which 
dies between week 8 and 9 of embryogenesis [18].  It has been shown that NaPi-IIb 
mRNA is present in the placenta [19], however protein expression and quantitative 
measurements of Pi absorption from placenta to embryo have not currently been 
investigated. 
 
1.2.1.2. NaPi structure and function  
All three isoforms of NaPi (IIa, IIb, and IIc) have recently been determined to possess a 
12-pass transmembrane domain (TMD) [20], replacing the original model of an 8 TMD 
protein established soon after the rat and human isoforms of these transporters were 
first cloned [21].  With regards to structure, NaPi proteins share no homology with other 
protein families and they exists as functional monomers with both the C and N terminus 
residing intracellularly, making them important target sites for protein-protein 
interactions and hormonal control [22].  For example, the Lys-Arg (KR) motif located in 
an intracellular linker region between TMD10 and TMD11 in NaPi-IIa is critical for 
parathyroid hormone (PTH) sensitivity and subsequent retrieval of transporter from the 
BBM [23] Another example is the TRL motif in the C-terminal region which forms the 
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basis for a PDZ-binding motif, a crucial protein sequence for NaPi function and retrieval 
[24] (in depth discussion in section 1.2.1.4).    
 
The process of shuttling fully functional NaPi proteins to and from the apical membrane 
does not involve recycling.  Instead, transporters which are targeted for internalization 
are partially detected by clathrin-coated pits, trafficked to early endosomes and targeted 
by lysosomes for degradation [25, 26].  Retrieval of NaPi-IIc is slower than NaPi-IIa, 
does not entail lysosomal degradation, and involves interactions with other cell 
structures such as microtubules [27].   
 
1.2.1.3 Kinetic properties of NaPis 
NaPi proteins utilize the free energy produced by the Na+ gradient across the cell 
membrane to actively transport Na+ and Pi at a 3:1 and 2:1 ratio (NaPi-IIa and NaPi-IIb, 
and NaPi-IIc respectively) [28] (Figure 1.2).  The only other cation that has been shown 
to be able to partially replace sodium in driving Pi transport has been Li+, which is able 
to replace at least one of the 3 Na+ ions utilized by NaPi-IIa and NaPi-IIb [29].  The 
NaPis can also be distinguished by their electrogenicity; NaPi-IIa and NaPi-IIb are 
electrogenic, whereas NaPi-IIc is electroneutral owing to the difference in Na+ and Pi 
transport ratio.  Once the transporters are translocated to the BBM, the only factors that 
influence transport kinetics are membrane potential and extracellular pH [28, 30].  
 
All three NaPi isoforms have a divalent phosphate (HPO42-) preference, thus pH is a 
strong determinant of Pi transport capacity as it affects the monovalent/divalent Pi 
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distribution in the lumen of the proximal tubule and the small intestine; divalent Pi 
anions are in abundance at a neutral to basic pH [31].  pH also affects transport kinetics 
in a very direct manner as the proton concentration within a solution directly modulates 
kinetics [31].  At pH 7.4, NaPi proteins share similar substrate affinities of 100uM for 
divalent Pi and 40mM for Na+ - these values are far below normal concentrations in the 
proximal tubule, therefore it is likely that these transporters function at close to their 
maximum rates in the kidney [32].  
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Figure 1.2.  Properties of kidney and intestinal Pi transporters 
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1.2.1.4. Regulation of NaPis  
The main regulators of renal NaPi-IIa and IIc are parathyroid hormone (PTH), dietary Pi, 
dopamine, 1,25 dihydroxyvitamin D3 (vitamin D) and FGF-23 (a phosphatonin which will 
be discussed in section 1.3).   
 
In mice and rats, PTH stimulation of renal PTH1 receptor, which is located on both the 
apical and basolateral side of the proximal tubule [32] results in a decrease of NaPi-IIa 
expression within minutes – NaPi-IIc expression alterations occur after a few hours [33].  
It is unknown if this same response occurs in humans.  Interestingly, PTH activates both 
protein kinase A and C pathways [34], which indirectly results in phosphorylation of a 
PDZ-containing protein NHERF1 at Ser77 and decreases the domain’s affinity for NaPi-
IIa [35]. NaPi-IIa binds to several PDZ domain-containing proteins (NHERF1, NHERF3) 
[36] and as demonstrated through the use of NHERF1-null mice, the interaction of 
NaPi-IIa with NHERF1 is crucial for apical stability and retention of this transporter [37].  
These mice exhibited hypophosphatemia and phosphaturia as well as a reduction in 
apical NaPi-IIa.  In contrast, NHERF3 ablated mice show no signs of alterations of 
NaPi-IIa expression or Pi excretion [38].  Recently, NHERF1 has also been shown to 
interact with intestinal NaPi-IIb through the use of NHERF1 knockout mice as well as 
confocal microscopy [39].  The lack of NHERF1 however, only seems to impair NaPi-IIb 
adaptation to low Pi diet conditions and thus its interaction with NaPi-IIb may not be as 
crucial for Pi transport in the intestine.   
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Dopamine has been shown to regulate NaPi-IIa by a mechanism similar to PTH with 
experiments utilizing mouse renal proximal tubule cells.  Protein kinase A and the cyclic 
AMP (cAMP) pathway are activated by dopamine, which then stimulates protein kinase 
C.  This results in the aforementioned phosphorylation of NHERF1 at Ser77 and the 
subsequent disassociation of the NaPI-IIa/NHERF1 complex [40]. 
 
Diet-induced, high serum Pi triggers an increase in urinary Pi excretion in a relatively 
acute manner (~1 hour), a mechanism which seems to be indistinguishable from PTH 
[41].  The signalling mechanisms attributed to acute changes in renal NaPis in response 
to dietary Pi are independent of the known factors that are directly affected by changes 
in dietary Pi (calcium, PTH, vitamin D, FGF-23); hence it is implied that the kidney may 
detect changes in Pi concentration in the plasma by an unknown sensing mechanism 
[42] (a more thorough review of renal Pi regulation and the gastro-renal Pi axis will be 
discussed in section 1.6).  Conversely, a low Pi diet leads to a more chronic adaptation 
of NaPi transporters since hypophosphatemia first increases plasma calcium 
concentration.  Increased plasma calcium then triggers feedback inhibition of PTH 
release and induces maximal renal Pi reabsorption by upregulating NaPi-IIa and IIc 
expression [25].   
 
Vitamin D induces genomic reduction of NaPi-IIa but increases NaPi-IIb protein in adult 
rats directly, post-transcription [43, 44].  This process occurs via an alteration of FGF-23 
levels (a phosphatonin discussed in section 1.3) [45]. In suckling rats, vitamin D 
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increases NaPi-IIb mRNA only, thus it can be concluded that the effect of Vitamin D on 
NaPi-IIb is age dependent [46] 
 
Very recent experiments have shown that NaPi expression can be altered by protein 
kinases that regulate insulin-like growth factor-1 (IGF-1) [47].  In these studies, 
serine/threonine protein kinase B-RAF was shown to upregulate both renal and 
intestinal NaPi-s expressed in oocytes.  When oocytes where co-expressed with NaPi 
and B-RAF or a water control and placed in a Pi bath, a larger intracellular current was 
generated and thus higher Pi uptake capability was produced in the oocytes co-
expressed with NaPi and B-RAF.  Thus far, only in vitro experiments have been 
conducted utilizing B-RAF, so its significance in regulating NaPis in humans has still not 
been determined. 
 
The mode of activation and regulation of intestinal NaPi-IIb is much less understood 
and great focus has been placed on investigating Pi absorption in this area.  As 
mentioned previously, NaPi-IIb is regulated mainly by vitamin D and serum Pi [44] with 
only 30% of intestinal Pi regulation occurring through the influence of vitamin D [48].  In 
depth regulation of NaPi-IIb (intestinal Pi absorption) will be discussed in section 1.5.   
 
1.2.1.5.  Knockout studies 
Segawa et al [49, 50] and Tenenhouse et al [49, 50] have conducted numerous studies 
using transgenic mouse models expressing various degrees of gene knockouts.  Renal 
NaPi-IIa -/- mice exhibit hypophosphatemia, hypercalcemia and hypercalciuria while 
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there is also a compensatory upregulation of NaPi-IIc protein expression [49, 50].   
NaPi-IIc knockout mice possess normal levels of serum Pi and excrete urinal Pi and the 
uptake of Pi into renal BBM is indistinguishable from WT mice [50] (Figure 1.3). The 
expression of NaPi-IIa remains the same in these NaPi-IIc -/- mice as well, which 
implies that the normal contribution of NaPi-IIc to Pi homeostasis is minor but may be 
particularly important under severe circumstances.   
 
Although NaPi-IIc is thought to only contribute a negligible role in overall Pi homeostasis 
from observations of the aforementioned mouse models, the transporter may have a 
more significant role in Pi transport in humans.  Mutations in NaPi-IIc in humans have 
been implicated as the cause of hereditary hypophosphatemic rickets with hypercalcuria 
(HHRH) [51-53].  This condition is characterised by renal Pi wasting which leads to 
hypophosphatemia and secondary rickets or osteomalacia.  As a result, studies 
focusing on this specific genetic condition suggest that NaPi-IIc may have more of an 
impact on Pi balance in humans.     
 
In the case of NaPi-IIb knockout mice, early embryonic lethality was observed, likely 
due to an impaired Pi absorption from maternal circulation.  By bypassing this 
phenotype and generating a tamoxifen inducible NaPi-IIb deficient model, groups have 
shown increased fecal Pi excretion and a 90% reduction in sodium-dependent Pi 
transport in the small intestine.  Despite this reduced intestinal Pi absorption, a ~40-
45% decrease compared to WT mice, the knockouts maintained a normal level of 
serum Pi possibly due to a compensatory upregulation of NaPi-IIa [54] (Figure 1.3).   
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Age dependent variations of the role of NaPi-IIb were also investigated by generating 
heterozygous knockout mice.  At 4 weeks, NaPi-IIb +/- mice exhibited a significant 
decrease in of NaPi-IIb mRNA and protein levels, along with impaired intestinal Pi 
transport and hypophosphatemia.  Compensatory upregulation of NaPi-IIa and IIc and 
increased circulating levels of FGF-23 were noted, but these changes were not enough 
to prevent hypophosphatemia [55].  In contrast, mice at 20 weeks maintained 
normophosphatemia, which highlights and reaffirms the importance of intestinal Pi 
transport during ontogenesies (44, 45).  Interestingly, these heterozygous mice at 20 
weeks did not show any changes in the expression of renal NaPi transporters or 
FGF23, yet still maintained a persistent hypophosphaturia.  These phenotypes mimic 
those of patients with human pulmonary alveolar microlithiasis, a disorder involving 
inactivating mutations in NaPi-IIb.  Those affected do not exhibit changes in plasma Pi 
concentration [56] yet concurrently have hypophosphaturia and low levels of FGF-23 
[57] (Figure 1.3).      
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Figure 1.3.  Summary of NaPi knockout mice phenotypes 
 
 
1.2.1.6. Inhibitors  
Pi transport by all isoforms of NaPi is blocked by nicotinamide and phosphonoformic 
acid (PFA) as they act as competitive inhibitors.  Nicotinamide is a compound which 
stimulates biosynthesis and halts catabolism of nicotinamide adenine dinucleotide 
(NAD) – NAD is a component cAMP generation which initiates a main pathway of NaPi-
IIa/IIc retrieval.   However, nephrotoxicity and gastrointestinal side-effects prevent their 
use as targets for Pi control in CKD patients [58] (further discussion of these blockers 
(specifically for intestinal NaPi-IIb) and their use in therapy will be discussed in section 
1.8.1.3).    
 
1.2.2. Sodium phosphate cotransporters – Type III (PiTs)  
Type III cotransporters (SLC20), PiT1 and PiT2, are similar in structure to the NaPis, 
however their roles were initially speculated to involve support of the actin cytoskeletal 
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network [59]. Unlike the type II NaPis, they have a preference for transporting 
monovalent phosphate (H2PO4-) with a 2:1 Na+:Pi transport stoichiometry (Figure 1.2).  
This difference in Pi preference leads to the fact that the PiTs function with a greater 
capacity at a lower pH as this alters the Pi composition to greatly increase the 
monovalent forms of circulating Pi [60, 61].  The affinities for Pi and Na+ are similar to 
those of Type II NaPis (< 100uM and ~50mM respectively), however PiTs are 
significantly less sensitive to pH; PiT1 in particular has been shown to have stable 
transport rates across a 3 pH unit range [32].  Also, unlike type II NaPis which are 
almost exclusively driven by Na+, Li+ has the ability to fully replace sodium in driving Pi 
transport in type III PiTs [61].  However, a result of this cation replacement is 
significantly reduced Pi transport rates – the serum concentration of Li is also relatively 
low, thus this phenomenon may have little impact on Pi homeostasis in general.      
 
Although mRNA for both PiT transporters are found across many cell types, detectable 
levels of protein expression for PiT1 is found throughout the small intestine and PiT 2 
protein on the BBM of kidney proximal tubules  [62], [60].  Similar to NaPi transporters, 
inter-organ PiT expression differs between species; in mice there does seem to be 
protein expression of PiT2 strictly in the ileum [63] [64] whereas rats, minimal PiT2 
protein is found in small intestine [62]. 
 
In associated knockout studies, it was shown that PiT2 was responsible for carrying out 
residual renal Pi transport in NaPi-IIa and IIc double knockout mice [50].  However, due 
to the fact that these cotransporters do not show rapid Pi-dependent regulation between 
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apical and basolateral membranes of these epithelial cells, it can be concluded that 
their expression is dependent on functions other than Pi homeostasis [20].  Some of 
these functions have been revealed to include roles in early liver development, bone 
matrix calcification, and cell proliferation [65-67]    
 
There is a strong interest in the role of PiT transporters in vascular calcification as they 
are more highly expressed in vascular smooth muscle cells (VSMCs) than Type II 
sodium phosphate cotransporters [68, 69] (more detailed discussion in section 1.8.1.2) .  
PiT1 is also important for normal liver growth since disruption of the PiT1 gene in mice 
leads to mid-gestation lethality due to severe defects in liver development [65].   
 
1.2.2.1. PiT regulation  
The abundance of PiT2 protein at the renal BBM is regulated by dietary Pi with 
experiments showing an upregulation of transporter protein following a chronic low Pi 
diet in rats [60].  According to the group’s time course studies, this adaptation took 
approximately 8 hours, much longer than changes seen to the renal NaPi transporters.  
Thus the signalling associated with this regulation can be deduced to involve NaPi-
independent pathways.  In contrast, protein levels of PiT1 do not seem to be altered by 
dietary Pi load [62].  PiT2 mRNA is also upregulated following vitamin D treatment in 
vitro [70], however the significance of this effect is unknown.   
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1.2.3. Sodium phosphate cotransporters – Type I 
The type I transporters also belong to the solute carrier family (SLC17) and are 
currently known to play a much smaller role in Pi homeostasis in the body.   
 
Although 9 separate homologues of the type I cotransporters have been characterized 
previously, recent discoveries place one of the NaPi homologues (SLC17a4) as an 
organic cation transporter in the small intestine and another (SLC17a7) an inorganic Pi 
transporter in the brain [71, 72].  Proposed theories for their expression in these regions 
involve intestinal urate and drug metabolite extrusion and mineral transport for neuronal 
function respectively.  The fact that type I transporters only share about 20% structural 
homology with the NaPis, [73] suggests that their mechanisms are not crucial for Pi 
handling and absorption in most organs.     
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1.3.  Phosphatonins 
 
A group of proteins known as phosphatonins have come into the foreground as primary 
regulators of Pi homeostasis due to their rapid phosphaturic effect. The term 
phosphatonin was coined to refer to an endocrine substance that acts to increase Pi 
excretion via a cAMP-independent pathway and reduces the function of 1a-hydroxylase 
to convert 25 dihydroxyvitamin D3 (calcifediol) to active vitamin D [7].  Fibroblast growth 
factor 23 (FGF-23) and its co-receptor Klotho are the most well described factors, as 
well as matrix extracellular phopshoglycoprotein (MEPE), frizzled-related protein 4 
(sFRP-4), and fibroblast growth factor 7 (FGF-7).  All four of these Pi-regulating factors 
were found and isolated from Pi-wasting tumors associated with tumor-induced 
osteomalacia (TIO) in various clinical disorders and serve to increase Pi excretion in the 
urine by directly acting on the number of sodium phosphate cotransporters expressed at 
the brush border membrane of the proximal tubule [7].     
 
1.3.1. FGF-23 
FGF-23 is an established and well-studied factor involved in Pi regulation which acts 
mainly at the renal proximal tubule.  FGF-23 is a 32 kDa protein that is expressed 
mostly in osteoblasts and osteocytes while structurally, it lacks a heparin sulfate binding 
motif which is characteristic of others in the FGF family – this enables it to act in an 
endocrine manner [74].  Gain of function mutations in FGF-23 cause autosomal 
dominant hypophosphatemic rickets (ADHR) and FGF-23 itself has been shown to 
reduce expression of renal NaPi-IIa and NaPi-IIc at the proximal tubule BBM [75] while 
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also decreasing circulating levels of vitamin D.   This discovery was made using 
transgenic mice overexpressing FGF-23 as well as wild-type mice treated with FGF-23, 
both of which showed a decrease in serum vitamin D [76, 77].  In a complementary 
fashion, FGF-23 null mice exhibited elevated levels of vitamin D [78], which was later 
discovered to be the result of the effect of FGF-23 inhibiting renal 24-hydroxylase 
activity, which catabolises vitamin D [79].  The reduction in vitamin D in turn, also 
serves to reduce intestinal Pi transport and decrease NaPi-IIb expression [80].  In order 
for FGF-23 to become biologically active, it requires another co-receptor; membrane 
bound Klotho (described in the following section).  Klotho first binds to an FGF 
receptor (FGFR) then forms a ternary structure with the C terminus of FGF-23 while the 
FGFR binds to its N terminus [75].  The location of action in which FGF-23 
downregulates NaPi expression is still debated since Klotho has been shown to be 
expressed in the renal distal tubules whereas almost all renal NaPi protein is located in 
the proximal tubules as previously discussed.  This observation suggests that there may 
be some signalling factor which originates from the FGF-23-Klotho complex in the 
proximal tubule [81].  Using FGF-23 as a biomarker for CKD has been a topic of 
discussion since elevated levels are seen before altered levels of PTH (an established 
indicator of CKD), but whether FGF-23 is the cause or effect of increased PTH is still to 
be determined.   
 
1.3.2. Klotho 
The importance of the Klotho protein in Pi metabolism was established in the last few 
years with the observation that the phenotypes of Klotho-deficient mice were almost 
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identical to mice lacking FGF-23 [78], [82].  It has now been confirmed that in order for 
FGF-23 to fully form an active complex and induce the aforementioned modifications in 
renal Pi transport and vitamin D levels, it must interact with a co-receptor known as 
Klotho.  The membrane-bound form of Klotho first establishes a binary structure by 
binding with certain isoforms of FGFR (1C, 3C, 4) in order to enhance its affinity for 
FGF-23.  This initial interaction with αKlotho and FGFR is the main event which 
determines the specific tissue target of FGF-23 [83].  Recent discoveries show that 
Klotho exists in both membrane bound (68kDa) and a secreted, circulating form 
(130kDa) [84, 85] with the circulating type acting on tangential pathways such as 
increasing cell surface expression of certain renal ion channels (e.g. TRPV5 and 
ROMK) (reviewed extensively in [86]).  The role of Klotho in Pi handling has been a 
relatively recent finding with data suggesting a strong relationship.  Utilizing a renal free-
flow micropuncture method, Hu and colleagues discovered that Klotho protein is found 
in proximal tubular fluid and directly inactivates BBM expressed NaPi-IIa resulting in 
phosphaturia [87].  The method of action was found to occur via Klotho’s 
glucuronidase activity and is completetly independent of interaction with FGF-23.  
Moreover, another isoform of Klotho, ßKlotho, has been shown to interact with human 
FGF-19.  ßKlotho protein is also expressed in the small intestine and is known to inhibit 
sodium-dependent bile acid transport [88].  Whether ßKlotho has any relevance to Pi 
handling similar to those of Klotho is still under investigation.   
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1.3.3. MEPE 
MEPE belongs to the group of small integrin-binding ligand interacting glycoprotein 
family (SIBLING) and is one of the most overexpressed proteins in diseases related to 
renal Pi wasting.  Although MEPE is derived from the cellular components of the bone, 
its mRNA is present in both the small intestine and kidney [17] while protein expression 
and bioactivity are most highly concentrated in the proximal tubule of the kidney; these 
findings point to the fact that MEPE may play a significant role in Pi homeostasis [89]. 
Through studies conducted utilizing an in-situ gut loop technique in rats, MEPE is 
currently the only phosphatonin known to directly influence intestinal Pi absorption [90].  
Following an intravenous (IV) MEPE infusion, rats exhibited a decrease in jejunal Pi 
absorption which was independent of changes in PTH, vitamin D (unlike following FGF-
23 infusion), or FGF-23 itself [90, 91].  It has also been confirmed that MEPE inhibits 
proximal tubular Pi reabsorption in rats following an IV infusion and single-nephron 
micropuncture and [91].  In these experiments, no changes were seen in glomerular or 
single-nephron filtration rate or filtered Pi load, which suggests that the primary target 
organ of MEPE is the kidney.  However, under certain physiological constraints (i.e. 
renal insufficiency), adaptation of the location of action of MEPE and its potential effect 
on intestinal Pi transport is still unknown. 
     
1.3.4. sFRP-4 
sFRP-4 is a phosphatonin that is highly expressed in tumors associated with renal Pi 
wasting and osteomalacia.  sFRP-4 was thought to play a role in the long-term 
regulation of renal Pi reabsorption following a high dietary Pi intake since sFRP-4 
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protein levels were upregulated in rat kidneys following a chronic high Pi diet [45] 
although levels of sFRP-4 were unaltered in animals on a low Pi diet.  It has been 
proposed that sFRP-4 decreases renal NaPi-IIa expression by inhibiting wnt pathways 
which serve to activate frizzled protein receptors. [92].  Its affect on other phosphate 
transporters has not been determined.    
 
1.3.5. FGF-7 
FGF-7 is also known as keratinocyte growth factor and was isolated from tumors of TIO 
patients [93].  As its alternative name suggests, FGF-7 is highly expressed in 
keratinocytes and its primary role is to stimulate wound healing [93].  In experiments on 
opossum kidney cells, it was shown that FGF-7 inhibits sodium-dependent Pi transport 
in opossum kidney cells [93] while also causing phosphaturia in rats in vivo [94].  The 
pathways involved in this method of action still remain unknown.   
 
 
1.4.  The kidney and Pi handling 
Pi homeostasis in healthy mammals is largely maintained through glomerular filtration 
followed by reabsorption of Pi across the kidney proximal tubule.  Approximately 80-
90% of total Pi in the plasma is reabsorbed at the proximal tubules, with only 15-20% 
taking place in the proximal straight tubule and the remainder in the proximal 
convoluted tubule [95].  
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1.4.1. Pi reabsorption at the proximal tubule 
Expression of NaPi-IIa at the apical membrane of the proximal tubule is largely 
responsible for Pi regulation, with a relatively lesser contribution by NaPi-IIc and type III 
sodium phosphate cotransporter, PiT2 [96].  Indeed, early kidney micropuncture and 
cell culture studies showed that sodium-dependent Pi transport is higher in the proximal 
convoluted tubules compared with proximal straight tubules and distal sections of the 
nephron [97].  This observation was later attributed to the higher Vmax of the sodium-
dependent Pi transport mechanism which directly correlates with the expression 
distribution of NaPi-IIa, specifically the early S1 and S2 segments [10].   
 
1.4.2. Regulation of renal Pi reabsorption 
Short term regulation of renal Pi resabsorption is carried out by the shuttling of NaPi-IIa 
and IIc within vesicles between the cytoplasm and the BBM of the proximal tubule [27, 
33].  The main regulators of renal NaPi-IIa and IIc are dietary Pi, PTH, vitamin D.  
 
1.4.2.1. Renal Pi regulation by dietary Pi 
A low Pi diet has historically been shown to increase renal Pi reabsorption to its 
maximum [98], with experiments using mice on a chronic low Pi diet showing an 
increase in sodium-dependent Pi transport in the proximal tubules with a correlating 
increase in NaPi-IIa protein but not mRNA [99]. However, expression of NaPi-IIc protein 
at the BBM and its mRNA expression was increased which suggests a compensatory 
mechanism under abnormal Pi conditions.  Rats given a similar low Pi diet however, 
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showed an increase in both NaPi-IIa protein and mRNA which highlights the 
discrepancies seen between species [60].   
 
Interestingly, an in vitro study which examined the effect of low Pi concentrations on 
cultured proximal tubule cells confirmed a rapid upregulation of Pi transport, suggesting 
that the cells were able to sense a change in Pi concentration independent of other 
circulating factors such as PTH [100]..  This proposed Pi-sensing mechanism by 
proximal tubule cells may also be linked to the calcium-sensing receptor (CaSR) since 
serum Pi and calcium levels are closely dependent on each other [96].  
 
1.4.2.2. Renal Pi regulation by PTH    
PTH levels in the body are regulated by two separate processes – first is the release of 
preformed PTH stored in the secretory cells of the parathyroid, and the second is the de 
novo synthesis of PTH [101, 102]. In accordance to these two processes, rapid changes 
in PTH result from the secretion of already fully formed PTH which is directly controlled 
by the binding of calcium to CaSR in the parathyroid gland [103, 104].  PTH release can 
also occur independently of calcium signals through the vitamin D pathway which 
inhibits PTH gene transcription and secretion in the parathyroid glands [105].  An 
increase in vitamin D is thought to act on the PTH gene by increasing the corresponding 
vitamin D receptor mRNA in the parathyroid gland [106].  Subsequently, the receptor 
forms a heterodimer with retinol X receptor and binds to vitamin D response elements 
within the PTH gene which represses its transcription.  Long-term adaptations resulting 
in altered PTH levels usually involve the synthesis of new protein.   
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PTH induces phosphaturia by directly acting on renal NaPi proteins at the BBM; serum 
levels are then acutely modified, with some changes reported within minutes [96].  This 
regulation was demonstrated following a low and high Pi diet gavage in rats, which 
caused changes in plasma PTH levels within 10-15 minutes [107].  PTH has also been 
shown to decrease activity of the Na/K ATPase at the basolateral membrane (BLM) of 
the proximal tubule which may indirectly affect Pi transport by altering the 
electrochemical gradient across the BBM [108].  For the specific pathways and 
mechanisms in which PTH regulates renal Pi transporters, please refer to section 
1.2.1.4. 
 
1.4.2.3.  Renal Pi regulation by vitamin D 
Calcifediol is hydroxylated and converted to active vitamin D in the kidney proximal 
tubule – subsequently, treatment of animals with vitamin D also stimulates Pi absorption 
in this tubule region [109].  In vitamin D deficient rats, protein and mRNA levels of NaPi-
IIa are significantly reduced in the kidney cortex.  Consequently, after a vitamin D dose, 
both NaPi-IIa protein and mRNA as well as sodium-dependent transport increase [43].  
 
The role of Vitamin D in renal Pi transport regulation is also intricately linked with factors 
such as levels of PTH and FGF-23.  The enzyme 25-hydroxyvitamin D3 - 1hydroxylase 
(aka 1-hydroxylase) converts calcifediol to active vitamin D – this enzyme is also 
stimulated by PTH through protein kinase A and C pathways [110, 111].  Interestingly, 
vitamin D has been shown to inhibit renal Pi reabsorption in rats which have undergone 
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thyroparathyroidectomy [112].  This result was later discovered to be a consequence of 
vitamin D acting on serum levels of FGF-23 [45].  For a detailed overview on FGF-23 
and other phosphatonins, please refer to section 1.3 
 
1.4.2.4.Other factors regulating renal Pi transport 
See phosphatonins, section 1.3. 
 
Metabolic acidosis is a condition in which blood pH is drastically lowered, resulting in an 
increase in renal excretion of Pi and ammonia to preserve bicarbonate and to excrete 
excess protons [113, 114].  Pi plays an essential role in correcting metabolic acidosis by 
acting as a buffer in extracellular fluid and more importantly, in urine [115].  
Phosphaturia is mediated by inhibition of renal Pi reabsorption, supported by the data 
that NaPi-IIa protein and mRNA as well as sodium-dependent Pi transport in BBM 
vesicles is decreased during this condition [115, 116].  This effect is independent of 
PTH, extracellular fluid volume, natriuresis, or plasma Pi concentrations [116] 
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Figure 1.4.  Summary of factors influencing kidney PI reabsorption 
 
 
 
1.5.  The intestine and Pi handling 
Although the kidney is the main player in body Pi homeostasis, there is increasing 
interest in the role of the small intestine in overall Pi handling.  Through recent 
advances in investigating Pi absorption, intestinal Pi absorption is thought to have a 
greater role in the maintenance of Pi balance than previously recognized.  There has 
also been an established connection between the intestine and the kidney to maintain 
postprandial Pi balance.  
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1.5.1. Pi absorption across the intestine 
Enterocytes mature during their transit from the crypt of Lieberkühn to the villus tip, thus 
only those enterocytes located in the mid to upper region of the villi express NaPi-IIb 
and are responsible for Pi uptake [117].  Studies have shown that instillation of Pi 
directly into the small intestine, specifically the duodenum, results in an acute increase 
in serum Pi concentration [54, 62] mediated by both NaPi-IIb and subsequent sodium-
independent pathways (both paracellular and transcelluar, discussed in section 1.5.3) 
[54].  Immunohistochemistry has revealed that type III transporter PiT1 protein is also 
located at the rat small intestinal BBM, however its role still remains unclear [62].  
Sodium-dependent Pi absorption across the intestinal BBM decreases with age in 
several mammalian species with a corresponding decrease in NaPi-IIb gene and 
protein expression [46, 118].  
 
1.5.2. Intestinal Pi regulation 
It is widely accepted that the type II transporter, NaPi-IIb, is responsible for Pi transport 
across the enterocyte BBM and provides the route for sodium-dependent transepithelial 
Pi absorption. Dietary Pi and vitamin D are considered to be the most important 
physiological regulators of this transporter with early experiments looking at NaPi-IIb 
adaptations to a low Pi diet.   
 
1.5.2.1. Intestinal Pi regulation by dietary Pi  
The foundations of what we know to be physiological luminal Pi concentrations along 
the human gastrointestinal tract result from early studies showing the range to be about 
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0.7-12.7mM, varying according to the content and timing of the last meal [119].  Pi, 
used as preservatives in processed foods, has been shown to possess a much higher 
bioavailability, resulting > 90% absorption in the intestine, compared with only 40-60% 
for naturally occurring dietary Pi [120].   
 
Hattenhauer and colleagues showed that NaPi-IIb protein expression increases at the 
BBM of the mouse intestine following a chronic low Pi diet [44], in order to maximize Pi 
absorption in this primary location.  Increased expression of NaPi-IIb can also be 
induced by injection of cholecalciferol (unhydroxylated vitamin D) intraperitoneally 24 
hours before tissue collection.  This supports previous studies showing that vitamin D 
increases the rate of Pi transport across the intestinal BBM vesicles [121].  Low Pi diet 
and vitamin D-induced increases in intestinal Pi transport also occur independently of 
one another, as shown by experiments utilizing vitamin D receptor knockout mice.  
These mice exhibited an increase in NaPi-IIb expression in response to a low Pi diet, 
which was comparable to wild-type mice [122].   
 
1.5.2.2. Intestinal Pi regulation by vitamin D 
Extensive studies have revealed the effects of vitamin D on intestinal Pi transport and 
NaPi-IIb (section 1.2.1.4), however vitamin D deficiency does not have a major effect on 
total intestinal Pi absorption in adult rats [123].  This may suggest that vitamin D plays a 
minor role in directly affecting Pi handling in the intestine, but its effects on other Pi 
regulatory factors such as FGF-23 still makes it an important factor in maintaining 
overall Pi homeostasis.   
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1.5.2.3. Intestinal Pi regulation by other factors 
Epidermal growth factor (EGF) [124] , glucocorticoids [118], estrogens [125], and 
metabolic acidosis [115] also have an effect on NaPi-IIb in more rare and clinically less 
relevant instances.  This section will focus on a brief summary of each.  
 
EGF is an important factor in the maintenance of gut morphology [126] and 
corresponding, high affinity EGF receptors are expressed along the entire GI tract [124].  
EGF treatment in rats decreases NaPi-IIb mRNA levels by approximately 50%. by 
reducing the NaPi-IIb gene promoter activity [124].  In rare clinical cases such as 
intestinal ischemia or injury-induced hyperphosphatemia, circulating EGF levels are 
elevated as well as endogenous EGF requirement in tissues [127], suggesting that EGF 
plays a part in intestinal Pi transport.   
 
Glucocorticoids are important regulators of overall enterocyte maturation and plasma 
levels of glucocorticoids are age-dependent [128].  Glucocorticoids inhibit intestinal Pi 
transport in an age-dependent manner with the highest level of inhibition occurring in 
suckling rats in contrast to the effect on renal Pi reabsorption which only occurs in adult 
rats [118].  The inhibitory effect of glucocorticoids on intestinal Pi uptake is mediated 
through changes in genomic and protein expression of NaPi-IIb. 
 
Estrogen is a main regular of calcium homeostasis since it affects calcium absorption, 
bone density, and vitamin D synthesis [125].  Estrogen stimulates intestinal sodium-
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dependent Pi transport by altering genomic and protein expression of NaPi-IIb [125], 
which may occur through estrogen receptors which are expressed along the intestinal 
epithelium [129]. 
 
The effect of metabolic acidosis on intestinal Pi transport is not as well characterized as 
in renal Pi reabsorption.  Gafter et al showed that metabolic acidosis in rats increased 
intestinal sodium-dependent Pi uptake with a parallel increase in expression of NaPi-IIb 
protein at the intestinal BBM [130].  However, in both rat and mouse animal models, Pi 
transport adaptations to metabolic acidosis does not extend to changes in genomic 
expression of NaPi-IIb, thus the importance of intestinal Pi absorption during metabolic 
acidosis is questionable.  An increase in intestinal Pi absorption would theoretically be 
helpful in buffering extracellular protons and compensate for loss of Pi from the bone 
during acidosis.   
  
Although dietary Pi and vitamin D have well-defined roles in altering intestinal Pi 
transport, phosphatonins have yet to become fully understood in this context.  Further 
research is crucial in obtaining knowledge of the intestinal actions of phosphatonins in 
order to increase the available targets for regulating Pi absorption across the intestine. 
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Figure 1.5.  Summary of factors influencing intestinal Pi absorption 
 
 
 
1.5.3. Passive paracellular and unknown transcellular Pi transport 
There is ongoing debate as to the specific proportion of intestinal Pi transport which is 
attributed to sodium-independent paracellular and transcellular routes.  Intestinal Pi 
absorption can be divided into a saturable, sodium-dependent transcellular pathway 
and a non-saturable sodium-independent pathway – the luminal concentration of Pi and 
the specific bioavailability of Pi in luminal contents determine which transport system is 
dominant.  
 
Sodium-independent Pi transport was revealed with very early studies using intestinal 
brush border membrane vesicles (BBMV) demonstrating that this transport pathway 
contributed to as much as 40-50% of total Pi transport [131, 132].  Thus, unlike the 
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kidney where sodium-independent Pi transport is negligible, this pathway seems to 
comprise a significant proportion of Pi transport which has been reported in both rat [44, 
70] and human small intestine [133].  This pathway is also not regulated by the classical 
modulators of intestinal Pi transport (e.g. vitamin D, dietary Pi), however experiments 
reveal that young animals and those treated with glucocorticoids have increased 
sodium-independent intestinal permeability [134, 135].  These results point to the fact 
that there may be an unidentified Pi transporter located at the BBM which is responsible 
for sodium-independent transcellular Pi transport.  Conversely, sodium-independent 
transport measured in BBMV may be an artifact of the technique and the measured Pi 
transport in that scenario could have occurred via an unregulated route.   
 
In depth in vivo examination of different routes of intestinal Pi transport arose from early 
studies in man which indicated that Pi absorption was mediated by active, sodium-
dependent transport at luminal concentrations below 2mM and by passive diffusion 
when over 2mM Pi [119].  Further studies using the conditional tamoxifen-induced NaPi-
IIb-/- KO mouse showed that NaPi-IIb is indeed accountable for 90% of Pi transport 
across the mice ileum.  However, only 50% of the total amount of Pi absorbed from the 
diet could be attributed to sodium-dependent, transepithelial Pi transport [54].  This 
conclusion reaffirms previous observations of a significant sodium-independent 
component of intestinal Pi transport, although whether this transport pathway occurs via 
a paracellular or transcellular route is still unidentified [133, 136]  
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Interestingly, tight junction proteins such as claudins and occludins, which provide a 
regulated and selective route for passive paracellular ion flow as well as epithelial cell 
adhesion [137] show subtle changes in expression under the stress of renal damage 
and CKD.  Studies show alterations in protein levels of claudin-1 and occludin, key 
constituents of tight junctions in intestinal epithelia, in patients with CKD [138].  Since 
tight junctions may regulate the still uncharacterized sodium-independent Pi transport 
pathway, these changes need to be investigated further to elucidate their consequence 
on intestinal Pi transport in CKD.  These data further support the notion that there is 
interplay between the small intestine and the kidney in Pi transport  
 
To summarize, it is probable that during fasting and low dietary Pi concentrations, Pi 
absorption is mediated mostly by NaPi-IIb.  However, when luminal Pi levels are 
elevated post-prandially, transport could also occur via a sodium-independent 
transcellular or paracellular pathway.  It is significant to note that both pathways have 
the potential to contribute to Pi imbalance, and whilst the NaPi-IIb knockout mouse 
model has advanced our understanding of the role of this protein in intestinal Pi 
absorption, further studies are necessary to define the mechanisms of sodium-
independent Pi transport.   
 
 
1.6. Kidney and GI tract:  a potential signalling axis 
In a publication by Berndt et al (2007), an ‘intestinal mucosal factor’ that directly 
influences renal Pi absorption was hypothesized [139, 140] . Their experimental work 
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showed a rapid increase in Pi excretion < 30 min. after duodenal instillation of 1.3M Pi 
[140]. This acute and specific phosphaturic effect, unlike the long-term adaptation to 
dietary Pi, was found to be independent of PTH and occurred without changes in 
plasma concentrations of Pi or other known phosphatonins such as FGF23 and sFRP4.  
The high concentration of Pi used in these experiments was an issue of concern as it 
may also alter physiological responses – the effects of a Pi solution with such high 
osmolarity on the intestinal lumen are unknown.  MEPE has been proposed as a 
potential candidate for this unknown phosphaturic factor since its mRNA is expressed in 
the small intestine and treatment of rats with MEPE increased Pi uptake at the intestinal 
BBM [90] (see section 1.3.3); however the specific mode of action has not yet been 
investigated.  
 
Interestingly, studies using NaPi IIb+/- and NaPi-IIb-/- KO mice have shown a role for 
NaPi-IIb in this potential cross-talk mechanism. Thus targeted deletion of NaPi-IIb is 
associated with decreased FGF-23 levels and decreased urinary Pi excretion in order to 
maintain normophophatemia [55, 141].  In support of these findings, data from previous 
studies have shown that in contrast to the well documented association between FGF-
23 and dietary Pi intake [142], acute non-dietary modulation of serum Pi levels within 
the normal range does not induce changes in FGF-23 [143, 144]. Therefore it appears 
that changes in intestinal Pi concentrations and/or intestinal Pi sensing may be the 
primary regulator of FGF-23 and that only supra-physiological changes in serum Pi 
concentration, such as during CKD, are associated with increased FGF-23 levels. 
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1.7.  Potential role of the liver in Pi handling 
 
The liver is an important metabolic organ well known for its function as a filtering unit for 
the body [145]  The liver weighs between 1200 and 1500g and, with exception of the 
skin, is the largest organ in the human body (approx 4-5% of body weight in newborn 
and 2-5% in an adult).  The blood supply to the liver also has two sources; the portal 
vein contributes approximately 75% of total circulating blood to the liver, the hepatic 
artery contributes the other 25%.  The liver is strategically situated in the circulatory 
system, receiving the portal blood that drains the stomach, small intestine, large 
intestine, pancreas, and spleen.  In this position, the liver plays a key role in processing 
nutrients from postprandial contents assimilated by the small intestine (Figure 1.7).    
 
 
Figure 1.6.  Schematic of hepatic portal vein location relative to the liver and small intestine 
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The liver metabolizes an extensive variety of compounds that are delivered by the portal 
and systemic circulations which include endogenous molecules (bile salts and bilirubin, 
key ingredients of bile) and exogenous molecules such as drugs and toxins.  The liver 
also has the capacity to convert important hormones and vitamins into a more active 
form.  Pi homeostasis relevant examples include the initial hydroxylation of vitamin D.  
One of the first steps of conversion of 7-dehydrocholesterol (cholecalciferol) and 
ergosterol into the active form of vitamin D also occurs in the liver through 
cholecalciferal 25-hydroxlyase in the mitochondria and microsomes [146].  Apart from 
this function of activating certain hormones, the liver also functions as a secretory organ 
through bile. 
   
Bile is a complex secretory product produced by the liver which eliminates many 
endogenous and exogenous waste products from the body, such as bilirubin and 
cholesterol [145] and potentially, Pi. The composition of the bile is modified significantly 
as a result of the absorptive and secretory properties of epithelial cells that line the 
intrahepatic and extrahepatic bile ducts.  
 
The Na-K pump present at the BLM of hepatocytes maintains a low cytosolic Na and 
high K concentration, as in most cells, while a basolateral ATP dependent Ca+ pump 
maintains Ca+ at an extremely low level, approx 100nM.  Hepatocytes use the inwardly 
directed Na gradient to fuel a variety of active transporters, such as the Na-H 
exchanger, Na/HCO3 cotransporter, and Na driven amino acid transporters (e.g. 
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SNAT4, LAT1/2 [147, 148]). Hepatocytes also take up glucose via the GLUT2 facilitated 
diffusion mechanism, which is insensitive to regulation by insulin.   
 
The idea that the liver plays a role in the context of Pi transport and homeostasis stems 
from the longstanding observation that serum Pi fluctuations occur following 
hepatectomy and in patients with liver diseases.  The initial consensus was that 
hypophosphatemia was always seen immediately following hepatectomy and proposed 
theories include the liver requiring extra metabolic needs, and Pi, from the blood for 
regeneration [149].  However, the magnitude of hypophosphatemia seen could not be 
accounted for by the demands of extra Pi uptake, thus other factors were investigated 
to explain this clinical observation.  Nafidi et al as well as Salem et al observed an early 
post-operative increase in fractional excretion of Pi post-hepatectomy which was 
independent of FGF23, FGF7, sFRP-4 and PTH (after day one) [150, 151]. 
 
In 2004, type II and III sodium phosphate cotransporters (NaPi-IIb and PiT1 and 2) were 
indentified in hepatocytes and cholangiocytes in rat liver.  Their possible roles in this 
organ involve regulating biliary Pi concentration since hepatocytes and cholangiocytes 
release ATP into bile which degrades to adenosine and Pi [13].  Excess Pi in the bile 
could potentially be taken up by these transporters to maintain Pi homeostasis.   
 
Another example of a functional process performed by the liver which is relevant to Pi 
regulation involves cathepsin B, the protease that cleaves a recently characterized 
phosphatonin MEPE into ASARM, another biologically-active and protease-resistant 
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phosphaturic factor that is also produced in the liver [152].     These findings combined 
with the knowledge that there is a PTH receptor in the liver that is also downregulated in 
a similar fashion to the renal PTH receptor under the constraints of CKD [153] further 
supports the notion that the liver may be a key player in Pi regulation and may be an 
intermediary in the proposed intestinal-renal axis of Pi homeostasis. 
 
Recent preliminary studies have shown that a phosphaturic factor may be excreted by 
the liver [154]. Using a rat model of partial hepatectomy, which show similar 
hypophosphatemia and phosphaturia as seen in patients, this group then utilized 
BBMVs prepared from the intestine and the kidneys of these animals.  These BBMVs 
showed a decrease in NaPi expression as well as a decrease in overall Pi transport.  
Utilizing a DNA microarray, this group revealed that this abnormal Pi transport was due 
to a defect in metabolism of nicotinamide, a known blocker of NaPi transport.  Further 
studies seeing if this pathway could be blocked were conducted on cell lines, so the 
application of this work to intact tissue is yet to be determined.   
 
 
1.8.  Pi imbalances and current treatment 
 
1.8.1 Hyperphosphatemia  
Hyperphosphatemia is a serious condition commonly associated with renal insufficiency 
and CKD.  In CKD, glomerular filtration rate (GFR) gradually decreases as time 
progresses, and renal Pi handling is altered by the progressive decline in the fraction of 
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filtered Pi that is reabsorbed - normally about 70% (see figure 1.1).  In patients with 
CKD, PTH is secreted in response to a decline in ionised serum calcium concentrations 
due to higher than normal Pi levels binding with serum calcium [155]. High PTH levels 
in turn, prompt calcium release from the bone and also increase urinary Pi excretion to 
normal serum Pi concentration.  Due to a decline in the number of functional nephrons 
in later stages of CKD, the phosphaturic actions of PTH become less effective.   
 
Patients with CKD also exhibit suppression of renal 1-hydroxylase activity which 
results in lowered plasma levels of active vitamin D [156].  This could be due to a 
decreasing functional renal mass and lower baseline 1-hydroxylase levels in general, 
a declining GFR which limits the distribution of calcifediol (precursor to active vitamin 
D), hyperphosphatemia itself [157], and increasing levels of FGF-23 seen in patients 
(see phosphatonins 1.3) [76, 158]. 
 
Hyperphosphatemia stimulates PTH release, and over secretion of PTH eventually 
leads to secondary hyperparathyroidism [159].  Furthermore, a decrease in CaSR 
expression in parathyroid glands of CKD patients may also be a contributing factor to 
secondary hyperparathyroidism [160], secondary hyperparathyroidism now also 
contributes to hyperphosphatemia by a feed forward mechanism by continuously 
stimulating the release of calcium phosphate from bone.  Although PTH increases renal 
Pi excretion, in late CKD this proves to be inefficient as there is a decrease number of 
functional nephrons.   
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The development of high blood Pi contributes to secondary hyperparathyroidism and 
cardiovascular (CV) complications, conditions which drastically increase mortality rates 
among CKD patients [161] (Figure 1.7).  There is a long established correlation 
between hyperphosphatemia and CV complications in end-stage CKD patients 
receiving dialysis, however hyperphosphatemia is also a risk factor for CV disease in 
patients with early stages of CKD [8].  In individuals possessing normal renal function, 
there is data proposing that even small changes in serum Pi may also be associated 
with an increase in age-related CV disease [162, 163].  Although there are no studies in 
man concerning the direct effects of Pi toxicity and CV disease, there has been recent 
findings exploring this causal link.  Finch et al investigated dietary Pi intervention on 
degree of calcification of the aorta of surgically induced CKD rats.  One group of rats 
with CKD were put on high Pi diets and another on Pi binders with or without additional 
low Pi diets.  A marked difference in aortic calcification was seen, with untreated CKD 
rats showing the most calcification, rats on Pi binders had a lowered calcification,  and 
those on both Pi binders and Pi-controlled diet had the least calification.  Furthermore, 
kidney tissue histology from animals on Pi binders and both Pi binders and diet control 
also showed the most normal ultrastructure, with minimal interstitial fibrosis and 
damage [164].  
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Figure 1.7.  Sequence of hyperphosphatemia-related conditions in CKD 
 
 
In early CKD, serum Pi may sometimes be within the normal, accepted range and thus 
may not be a reliable first marker for altered Pi handling.  This fact is emphasized with 
the findings that increased serum FGF-23 (with or without combined low urinary Pi 
excretion) and low serum Klotho all correlate with an increase vascular calcification 
and high morbidity in CKD patients with normal serum Pi levels [165-167].   
 
1.8.1.2 Vascular calcification 
Vascular calcification is a serious condition associated with CKD and lends to the high 
mortality rates in this patient group as mentioned in the above section.  The condition 
involes ossification (deposition of calcium phosphate precipitate products) within arterial 
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vessel walls which causes them to harden and restricts blood flow.  Calcification of 
vascular smooth muscle cells (VSMC) is stimulated by elevated extracellular levels of 
Pi, calcium and PTH which are all commonly observed in patients with CKD [168].  The 
actual process of calcification during hyperphosphatemia involves further differentiation 
of VSMCs into osteoblast-like cells which is promoted by transcription factors Runx2 
and CBfa1 [169].  This leads to expression of a broad range of genes related to the 
osteoblast phenotype (Gla protein and alkaline phosphatase)[169, 170].   
 
Pi uptake by VSMCs involve both sodium-dependent and independent pathways [69].  
The saturable, sodium-dependent Pi transport mechanism is mediated by type III 
transporters PiT1 and PiT2 [68], whereas expression and function of the type II NaPi 
transporters are minimal [69].  Increased expression of both PiT1 and PiT2 is thought to 
mediate vascular calcification during CKD which would result in an increase in Pi 
absorption into VSMCs and trigger the osteogenic differentiation [171].  Although both 
PiT1 and PiT2 are upregulated in VSMCs during CKD, it has been recently shown in 
mice that the role of PiT1 and PiT2 in VSMCs is redundant in the specific context of 
vascular calcification [172].  In this study, a VSMC-specific, PiT1 knockout mouse 
model of CKD showed upregulated PiT2 protein with an equivalent amount of vascular 
calcification as wild type mice following dietary Pi loading.  
 
1.8.1.3. Treatment for hyperphosphatemia 
Current treatments for high blood Pi include dietary Pi control as well as oral Pi binders, 
however these therapies prove to be substandard in regulating serum Pi in and may 
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even contribute to malnutrition and acceleration of calcification in soft tissues as well as 
a spectrum of unpleasant side effects such as gastrointestinal discomfort [173].    
 
Novel Pi binders are frequently studied with the goal of optimizing Pi binding capacity 
and minimizing side effects.  One compound being investigated in stage III clinical trials 
is ferric citrate hydrate (FC).  Experiments conducted in normal rats have shown that FC 
significantly decreases Pi absorption across the intestine whilst increasing fecal Pi 
excretion to a degree comparable to calcium carbonate [174].  When FC is 
administered to adenine-induced CKD rats, there is a reduction in aortic calcification, 
serum PTH levels and the severity of parathyroid hyperplasia [174].  In patients, FC 
treatment is effective at reducing serum Pi concentrations and the results of early 
studies suggest that FC may also increase levels of iron and iron storage capacity in the 
blood; this finding could imply that CKD treatment costs involving additional anemia 
could be reduced with the use of FC  [175]. 
 
Another treatment strategy currently under investigation is the idea to potentially target 
the process of intestinal Pi absorption to reduce CKD-induced hyperphosphatemia   
Data from NaPi-IIb KO mice with adenine induced CKD have confirmed positive results 
from this approach by showing that the absence of NaPi-IIb partially attenuates 
hyperphosphatemia [141].  However, combined with the known Pi binder, Sevelamer, 
hyperphosphatemia is completely normalized; this finding emphasizes that both NaPi-
IIb dependent and independent processes contribute to elevated Pi serum levels in 
CKD [141].  Future treatment options are envisaged to revolve around targeting NaPi-
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IIb dependent Pi transport combined with using Pi binders to patients on dialysis.  
Known inhibitors of NaPi-IIb, nicotinamide and phosphonoformic acid (PFA), which 
competitively inhibit NaPi transporters in vitro have varying effects on transport in in vivo 
CKD animal models as well as CKD patients [123, 176, 177].  Daily administration of 
nicotinamide to CKD rats decreased Pi uptake across the jejunal BBM and was 
associated with improved blood Pi levels [178]. Treatment of hemodialysis patients with 
nicotinamide also resulted in amelioration of hyperphosphatemia, although this was also 
coupled with varying gastrointestinal side effects which may prevent its clinical use 
[179].  More alarmingly, thrombocytopenia has also been reported in certain dialysis 
patients who were receiving nicotinamide treatment for 3 months or more [180].  Whilst 
PFA administered to CKD induced rats show an increase in phosphaturia [177], it does 
not appear to fully attenuate hyperphosphatemia. [177, 181].  
 
1.8.2. Hypophosphatemia 
Hypophosphatemia may be attributed to poor diet, malabsorption of Pi, or inherited 
conditions affecting Pi reabsorption in the kidney such as hypophosphatemic rickets 
and X-linked hypophosphatemia (XLH) [182].  When hypophosphatemia is allowed to 
go untreated, further complications occur in the form of respiratory failure as a result of 
muscle weakness and other conditions involving the muscles such as rhabdomyolysis 
[183].   
 
Hypophosphatemia in pediatric patients leads to much more severe consequences due 
to the high demand for Pi and calcium to support both skeletal and somatic growth and 
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development.  Prolonged hypophosphatemia in children can occur as a consequence of 
insufficient dietary intake or vitamin D deficiency, leading to calcipenic rickets.  The 
reduction of available calcium in the intestine leads to elevated levels of serum PTH 
(stimulating release of calcium from the bone) which then triggers the internalization of 
renal NaPi-IIa and NaPi-IIc.  This results in renal Pi wasting and hypophosphatemia 
[184].      
 
Renal Pi wasting can also be a consequence of phosphopenic rickets, but can also 
develop as a result of disorders which directly affect Pi homeostasis such as excessive 
secretion of FGF-23 (in TIO), mutations in genes encoding FGF-23 (ADHR), PHEX 
(XLH), and DMP-1 (autosomal-recessive hypophosphatemic rickets) or inactivating 
mutations in renal Pi transporter NaP-IIc (hereditary hypophosphatemic rickets with 
hypercalcuria) [185].  PHEX and DMP-1 are known factors upstream of FGF-23 that 
contribute to its synthesis in the bone [186]. 
 
Skeletal growth abnormalities associated with hypophosphatemia in pediatric patients 
depend on the severity of hypophosphatemia and the age of onset - young infants 
develop deformities in their weight bearing limbs with crawling infants’ forearms being 
particularly affected, while bow-legged (genu varum) phenotypes appear in toddlers.  
Older children and adolescents generally show different conditions such as muscle 
weakness and pain in the lower limbs which are magnified by exercise.  Other clinical 
features consist of growth retardations, dental deformities leading to abscesses, skulll 
deformities, spinal curvature, and joint swelling and pain [185]. 
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1.8.2.1. Treatment for hypophosphatemia 
Current treatment for calcipenic rickets involves oral loading of vitamin D, its synthetic 
analogue 1-hydroxyvitamin D3, and calcium supplementation.  Individuals with 
phosphopenic rickets are treated with Pi supplements combined with vitamin D or 1-
hydroxyvitamin D3.  Although these treatments address the issue of hypophosphatemia, 
their success in minimizing bone growth defects in later life are variable [187].   
 
Through recent advantages in the understanding of the pathogenesis of familial 
hypophosphatemic rickets, novel therapeutic options for the management of these 
disorders are under investigation.  The latest studies involving a cohort of patients with 
XLH show promise of increasing serum Pi levels through treatment with calcitonin [188].  
This hormone acts via its receptor on osteocytes [189] to inhibit the release of FGF-23 
and reduce the renal Pi wasting characteristics of this disease.  Studies using the Hyp 
mouse (a murine homologue of XLH), show that treatment with an anti-FGF-23 
neutralizing antibody results in improved Pi balance, bone growth, and reduced muscle 
weakness [190].   More recently, further studies using the Hyp mouse and also the 
Dmp-1 null mouse show that a newly described selective, pan-specific FGFR inhibitor 
also corrects hypophosphatemia as well as enhances bone growth, increases 
mineralization, and restores growth plate organization [191].  An important note is that 
inhibition of FGFR did not influence renal NaPi-IIa expression or the fractional excretion 
of Pi, signifying that the amelioration of hypophosphatemia may have been mediated 
via another route such as intestinal absorption of Pi [191].  Recombinant human growth 
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hormone (rhGH) has also been suggested as a standalone or adjunct to standard 
therapy for XLH, however this treatment still remains debatable as data show variability 
in benefits in terms of bone growth.  Some studies present convincing results showing 
increases in truncal height leading to a disproportion throughout the body, while other 
studies actually point to an increase in mortality – the current benefit to risk ratio is 
currently under review [192] 
 
Another potential treatment for hypophosphatemia in early stages of study is the 
potential to directly stimulate the intestinal Pi transport process in order to increase 
dietary Pi absorption, increase serum Pi levels, and promote bone growth in 
phosphopenic rickets.  However, regardless of the treatment combination chosen for 
the patient-specific needs, the need for early diagnosis and promptness of treatment is 
crucial and can result in steering children with XLH towards normal growth [193]. 
 
 
1.9. Project aims 
 
Sprague Dawley (SD) rats were used in these studies for a variety of reasons.  Rats are 
a good animal model to study body Pi balance as their regional expression of sodium-
phosphate transporters is most similar to humans.  Thus, the results from these studies 
may have a more direct, translational aspect than using mice.  Organs that are 
manipulated in the experiments (intestine, kidney and vessels/veins) are also more 
easily handled in rats compared to mice, as the larger overall size of these tissues in 
Chapter 1 
 
 
67 
rats leads to a decrease in potential damage from utilization.  Intestinal and renal brush 
border tissue collected for analysis is also more abundant in rats compared with mice. 
  
The aims of the project were to: 
   
1.  Define the reasons for discrepancies in intestinal Pi transport previously reported 
using different techniques for measuring Pi transport.  Specifically, Pi uptake using the 
in vitro everted sleeve was compared to the in situ intestinal loop methods.  
 
2.  Elucidate components of active/passive Pi transport by using an ex vivo intestinal 
perfusion model. 
 
3.  Replicate in vivo experiments conducted by Berndt et al (2007) with a more 
physiological intestinal luminal concentration of Pi (10mM) as well as the 1.3M 
concentration that Berndt et al utilized [139, 140].  To determine whether or not there is 
a duodenal phosphaturic factor working following an elevated level of Pi in intestinal 
luminal fluid, and to also examine NaPi-IIa and NaPi-IIc expression at the renal BBM 
under these experimental conditions.   
 
4.  Conduct in vivo experiments to make conclusions regarding the role of the liver as a 
potential storage organ for Pi during the intestinal Pi uptake process.
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2.0.  Assessment of regional differences in intestinal Pi transport  
using in vitro and in situ techniques 
 
2.1.  Introduction 
 
Hyperphosphatemia is one of the major associated conditions of CKD, with recent 
studies suggesting that even small changes in serum Pi may be linked to a higher 
mortality rate in this subset of the population [194].  With declining renal function in 
patients with CKD, the small intestine becomes the next organ to target in regulating Pi 
transport.  Unfortunately, the mechanisms and control of Pi transport in the intestine are 
incompletely understood with emerging data gathered from a wide variety of methods 
conflicting with data from other studies.   
 
There are opposing views concerning the contribution of specific regions of the intestine 
to overall Pi transport as well as the proportion of transport attributed to sodium-
dependent, active transport and passive transport (either paracellular or transcellular).  
These variations in opinion stem from data gained through a large spectrum of methods 
currently being employed to investigate Pi transport.  Species-specific differences in the 
intestinal region where the highest Pi transport takes place (e.g. mouse ileum vs. rat 
jejunum) also produce results which may seem paradoxical.   
 
Intestinal Pi transport can be categorized as active or passive, the former involving the 
activity of sodium phosphate cotransporters and the latter occurring paracellularly or 
Chapter 2 
 
 
69 
through an unknown and/or unregulated transcellular pathway. Early studies which 
focused on intestinal brush border membrane vesicle (BBMV) experiments revealed a 
Pi transport system that was highly sodium dependent, with a Kt of around 0.1mM [195, 
196].  Following this discovery, the type II sodium phosphate cotransporter, intestinal 
NaPi-IIb, was cloned and characterized by expression in oocytes.  Upon further 
analysis, this transporter was eventually found to be responsible for the majority of 
intestinal Pi transport [197].  The type III sodium phosphate cotransporter, PiT1, is 
expressed ubiquitously throughout the small intestine [62].  However, its role in overall 
Pi homeostasis is thought to be minimal due to a lack of acute, Pi-dependent regulation 
of its expression at the BBM [62], the site of the rate-limiting step for transcellular Pi 
transport. 
 
In contrast, in vivo studies using the entire rat GI tract show that relatively little Pi 
transport is sodium-dependent [198].  Indeed this finding, which utilized a novel method 
of radiolabeled Pi tracking, confirmed early observations of a sodium-independent 
component of intestinal Pi transport [136]; it is still unclear whether this “passive” mode 
of transport occurs via a transcellular or paracellular route.  Therefore in contrast to 
renal Pi transport, where it has been established that sodium-independent Pi transport 
is insignificant, diffusive pathway  contributes a large amount to overall intestinal Pi 
transport in both rats [44, 198] and man [133].  
 
The role of tight junction proteins such as claudins and occludins, which provide a 
regulated and selective route for paracellular ion transport, is still unknown in the 
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context of epithelial Pi transport.  It has been shown that intestinal claudin proteins 
undergo subtle changes in expression as a response to renal damage and CKD [137].  
Studies also show that there are alterations in protein levels of claudin-1 and occludin, 
key constituents of tight junctions in intestinal epithelia, in patients with CKD [138].  
Since tight junctions may regulate the still uncharacterized sodium-independent Pi 
transport pathway, these changes need to be investigated further to elucidate their 
consequences for intestinal Pi transport in CKD.   
 
Detailed, regional specific, Pi transport patterns under both sodium and sodium-free 
conditions however, is still not well established in the intestine.  Directly comparing 
methods of measuring Pi transport is important to determine the benefits and pitfalls of 
each technique and eventually to establish which method is a more adequate model for 
Pi transport. 
 
2.1.1.  Aims of this study 
1.  To compare the rates of sodium-dependent Pi transport utilizing two distinct in vitro 
and in situ techniques in five regions of the intestinal tract – the duodenum, jejunum, 
ileum, proximal colon, and distal colon.  Three different concentrations of Pi in the 
uptake buffer will be used to represent low, normal, and post-prandial Pi levels in the 
intestinal lumen (0.1, 1, and 10mM respectively).   
 
2.  To compare the rate of Pi transport (in the presence of sodium) across the five 
aforementioned intestinal regions using in vitro and in situ techniques. 
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3.  To determine changes in epithelial structure using electron microscopy to examine 
whether observed changes in Pi uptake reflect altered morphology or tissue damage as 
a consequence of the experimental protocols used. 
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2.2.  Materials and methods 
 
Ethics Approval: all experiments were performed under a UK Home Office Project 
license and protocols were approved by the Ethics Committee at University College 
London.  All surgeries were performed under general anesthesia (details are given 
under relevant sections, below). 
 
2.2.1.  Animal model 
Male Sprague Dawley (SD) rats of body weight 250g-300g were obtained from Charles 
River laboratories (UK) and used in accordance with the Animals (Scientific 
Procedures) Act 1986.  Rats were allowed ad libitum access to standard rodent chow 
containing 0.52% phosphate (Diet RM1, SDS Ltd, Witham, Essex UK) and water. 
 
2.2.2.  In vitro everted intestinal sleeve technique 
The everted sleeve technique exposes the mucosal surface of the intestinal segment to 
the uptake buffer containing radiolabelled phosphate – this allows direct measurements 
of Pi uptake across the intestinal BBM (Figure 2.1).  The validation of this preparation 
and optimal conditions for measurements has been determined [199].  Sprague-Dawley 
rats were anesthetized using an intraperitoneal (IP) injection of pentobarbitone sodium 
(Pentoject, Animalcare York, UK), 45mg/kg body weight, and specific regions of 
intestine (duodenum, jejunum, ileum, proximal colon, distal colon, each about 2-4cm 
long) were removed from the animal.  The duodenum was taken ~1cm from the 
stomach pylorus, jejunum was taken ~1cm distal to the ligament of Treitz, ileum began 
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about 3cm proximal to the cecum, proximal colon began 3 cm distal to the cecum, and 
the distal colon about 2 cm from the anal sphincter.   A maximum of two tissue samples 
per specific segment were used in each animal. The order of tissue removal was 
randomized, and a maximum of four segments were taken from any one rat so as to not 
compromise tissue viability.   
 
The segment lumen was first flushed through with room temperature, isotonic saline to 
remove any debris in the lumen.  The intestine was then everted on a glass rod and 
secured with ligatures at the top and bottom edges.  The tissue was subsequently 
incubated for 5 min in a buffer containing 16mM Na-HEPES, 3.5 mM KCl, 10mM 
MgSO4, 1mM CaCl2, and 125mM NaCl, which was oxygenated with 100% O2 and 
stirred constantly with a magnetic stirrer.  The tissue was then incubated for 2 min in 2 
mL of Pi buffer containing 10mM glucose, 0.1, 1, or 10mM KH2PO4 and 0.74 MBq 32P 
(Perkin Elmer, Bucks, UK) adjusted to a pH of 7.4 (Figure 2.1).  A 2 min uptake period 
chosen for Pi uptake since this was in the middle of the linear period of Pi uptake[200], 
and was also brief enough to allow minimal 32P to reach the serosal side of the tissue.  
Choline chloride (ChCl) was used as an iso-osmotic substitute for sodium chloride to 
allow determination of sodium-free Pi transport.   
 
Following the 2 min incubation period, the tissue was removed from the incubation 
buffer and the tissue was washed for 10 min at room temperature with saline or ChCl 
containing Pi at a 10x greater concentration than the one used in the uptake solution, 
This was to displace radiolabelled Pi bound to the tissue surface. A final wash was then 
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carried out using phosphate buffered saline (PBS) for 5 min. These two washes were 
sufficient to displace most of the bound 32P while retaining 32P already transported into 
enterocytes.  The tissue was then removed from the glass rod and a small segment 
from the middle of the tissue (~100 mg) was taken, weighed and digested overnight in 
Solvable (Perkin Elmer, MA, USA).   
 
 
 
 
Figure 2.1.  Diagram of in vitro  everted sleeve technique method used for measuring Pi uptake 
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2.2.3.  In situ intestinal closed-loop technique 
The jejunum was utilized for the closed loop technique due the higher NaPi-IIb protein 
expression in this region of rat small intestine [12].  The closed loop method provides 
maximum exposure to the Pi containing buffer in the segment with highest expression 
of phosphate transporter.    
 
The jejunum was identified (starting at the ligament of Treitz) and a 5cm segment was 
securely tied off with ligatures.  An opening was made at either end of the section; a 
cannula-sheathed 19-gauge needle was inserted at the top and secured with another 
ligature (Figure 2.2).  A 37oC warmed solution (0.9% saline or 154mM choline chloride 
[ChCl]) was flushed through this section to remove any food debris.  Following this, air 
was flushed through to remove as much solution as possible, then 500L of 32P radio-
labelled (0.37Mbq) HEPES phosphate solution (16mM Na-HEPES, 140mM NaCl, 
3.5mM KCL, 1/5/10/15mM KH2PO4, pH 7.4) was instilled via the cannula-sheathed 
needle.  When the solution was visible about halfway down the section, the bottom 
loose ligature was tied off, and after the complete 500L was instilled the needle was 
carefully removed and the ligature was tightened distal to the cannula entry (Figure 
2.2).  For experiments involving sodium-free buffer, saline was replaced with ChCl with 
all other concentrations of solutes remaining the same.  Osmolarity of the HEPES buffer 
was assessed using a freezing point depression micro-osmometer (Model 3M, 
Advanced Instruments Inc, Massachusetts, US) and all solutions were within isotonic 
range (290-310 mOsm/L).  Blood samples from the femoral artery were obtained at 10, 
20, and 30 min following Pi instillation and collected in tubes containing 
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ethylenediaminetetraacetic acid (EDTA), an anticoagulate.  Plasma was obtained after 
spinning down blood samples at 6000rpm for 10 minute at 4oC and the data presented 
shows plasma Pi values at 30 min.   
 
Calculations of Pi transport were performed by taking the 32P counts, converting this to 
nmole Pi uptake, and normalizing to 100mg intestinal tissue (in vitro experiments) or  
5cm of intestinal tissue per 1mL plasma collected (in situ experiments).   32P counts 
were measured with a Packard tri-carb 2900tr scintillation counter using 4mL  Ultima 
Gold (Perkin Elmer) scintillant solution to which was added 50uL plasma or 100uL 
digested intestinal tissue in triplicates.  The average from these triplicates was taken 
and converted to absolute Pi uptake in nmole units using values for initial counts of 
undiluted 32P instillate.   
 
Figure 2.2. Diagram of the in situ intestinal closed-loop technique used to measure Pi absorption 
Loose ligature in blue is tightened mid-way through Pi instillation.  After full Pi instillation and cannula 
removal, the top blue ligature was tightened to contain Pi buffer in the specific intestinal segment.   
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2.2.4.  Statistical analysis of Pi uptake data 
Data is presented as mean ± SEM.  A student’s paired t-test or an ANOVA, as 
appropriate, was used and group differences were stated as statistically significant if P 
< 0.05; n represents the sample size of each experiment.   
 
2.2.5.  Electron microscopy (EM) of intestinal tissue from in vitro and in situ 
techniques 
Segments of intestine were fixed following “mock” uptake experiments conducted in the 
exact manner as described previously. The aim was to assess possible differences in 
morphology following the two respective methodologies.  A 1cm segment of intestinal 
tissue was then removed and fixed in ice-cold glutaraldeyhyde for 24 hours.  The tissue 
was then sent to the EM core facility at the Royal Free Hospital for embedding, slicing, 
and imaging.  The following protocol was used for processing of the tissue: 
 
- washing and secondary fix in osmium tetroxide 
- dehydration (ethanol gradients up to 100%) 
- resin (Lemix, TAAB labs, UK)/ethanol 1:1 overnight 
- 100% resin for 24 hours 
- embedding at 65oC overnight 
 
EM Images were obtained within 1-2 weeks of the above procedure using a Japanese 
Electron Optics Laboratories electron microscope (model JEOL 1200EX). 
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2.3.  Results 
 
2.3.1.  Sodium-dependent Pi transport:  in vitro everted sleeve 
Sodium-dependent Pi transport was measured using sections from duodenum, jejunum, 
ileum, proximal colon, and distal colon utilizing the in vitro everted sleeve technique.  
Uptake buffer containing 0.1mM, 1mM, and 10mM Pi was used and “sodium-free” 
experiments were achieved by using ChCl as a replacement for NaCl.  Results are 
shown in Figure 2.3.   
 
In both the duodenum and the jejunum, sodium dependency was seen at all three Pi 
concentrations used. In the ileum and proximal colon, similar rates of Pi were observed 
in the presence or absence of sodium.  In the distal colon there was an apparent 
sodium dependent Pi uptake at 10mM Pi.  The distal colon also transported Pi at a 
similar rate to the jejunum and the duodenum, which has not been previously reported.  
P values (Na vs ChCl):  Duodenum 0.1mM = 0.00481, 1mM = 0.0341, 10mM = 0.0228; 
Jejunum 0.1mM = 0.005, 1mM = 0.00698, 10mM = 0.00108; Ileum 0.1mM = 0.338, 
1mM = 0.411, 10mM = 0.269; Proximal colon 0.1mM = 0.678, 1mM = 0.653, 10mM = 
0.837; Distal colon 0.1mM = 0.0449, 1mM = 0.374, 10mM = 0.00101 (Figure 2.3). 
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Figure 2.3.  In vitro everted sleeve. Sodium-dependent and sodium-independent Pi transport in five different intestinal regions  
Shaded bars represent Pi uptake in the presence of sodium while checkered bars represent Pi uptake with a sodium-free buffer (ChCl).  Data is 
presented as mean ± SEM with n = 5-7 across all intestinal regions and Pi concentrations utilized.   * = P < 0.05, ** = P < 0.01, *** = P < 0.005. 
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2.3.2.  Sodium-dependent Pi transport:  in situ intestinal closed-loop technique 
Sodium-dependent Pi transport was measured in situ using the closed-loop technique and 
using the same three concentrations of Pi as used for the in vitro technique.  Results are 
shown in Figure 2.4.   
 
The jejunum exhibited the greatest Pi transport of all intestinal regions used, followed by 
the duodenum and the ileum.  Sodium dependency was only seen in the jejunum and at 
two concentrations in the ileum (1mM and 10mM Pi).  P values (Na vs ChCl):  Duodenum 
0.1mM = 0.339, 1mM = 0.907, 10mM = 0.978; Jejunum 0.1mM = 0.0292, 1mM = 0.0406, 
10mM = 0.0156; Ileum 0.1mM = 0.176, 1mM = 0.019, 10mM = 4.6 x 10-5; Proximal colon 
0.1mM = 0.711, 1mM = 0.295, 10mM = 0.196; Distal colon 0.1mM = 0.946, 1mM = 0.904, 
10mM = 0.753 (Figure 2.4). 
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Figure 2.4.  In situ intestinal closed-loop.  Sodium-dependent and sodium-independent Pi transport in five different intestinal regions 
Shaded bars represent Pi uptake in the presence of sodium while checked bars represent Pi uptake with a sodium-free buffer (ChCl).  Data is presented 
as mean ± SEM with n = 5-7 across all intestinal regions and Pi concentrations utilized.  * = P < 0.05, ** = P < 0.01, *** = P < 0.005. 
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2.3.3.  Regional differences in transport using in vitro and in situ techniques  
Differences in the rate of Pi transport between the five intestinal regions were compared 
using three concentrations of Pi (0.1, 1, 10mM) in the presence of sodium.  Results are 
shown in Figure 2.5 using data from Figures 2.3 and 2.4.   
 
The in situ method always resulted in lower measured Pi transported overall.  The 
jejunum was the site of highest Pi transport in all experiments, with the duodenum 
ranked second for the majority of Pi concentrations used.  For the rest of the segments 
however, variability was seen.  The most noticeable differences occurred in the ileum 
and the proximal colon, where data from in situ experiments showed that the ileum had 
measurable Pi transport whereas the in vitro data suggests that ileal Pi transport was 
negligible.  Interestingly, the distal colon transported Pi at a similar rate to the 
duodenum using 1mM Pi in situ, and using 10mM Pi in vitro which has not been 
previously reported (Figure 2.5).   
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Figure 2.5. Regional intestinal Pi transport. Differences between in vitro and in situ techniques 
Data is presented as mean ± SEM with n = 5-7 across all intestinal regions and Pi concentrations 
utilized. 
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2.3.4.  Electron microscopy of intestinal tissue 
Images were obtained with the help of an on-site EM core facility at the Royal Free 
Hospital to visualize intestinal tissue morphology following the two different types of 
experiment procedures explored above.  Each segment was treated in the same 
manner as described in the methods section and immediately fixed in cold fixative 
(glutaraldehyde) and processed.  Intestinal tissue appeared to be intact based on tight 
junction observation in high magnification (10-50,000x magnification, JEOL 1200EX 
electron microscope) (Figure 2.6). 
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Figure 2.6. EM images of intestinal tissue obtained following in vitro and in situ methods of 
measuring Pi uptake 
Tight junctions (TJ) are shown in red text with appropriate scale bars in the bottom right corner.     
In vitro        In situ 
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2.4.  Discussion 
 
A large range of methods have been used to study solute transport across the intestinal 
epithelium but comprehensive comparisons between these techniques have not been 
previously conducted.  The aim of experiments discussed in this chapter was to 
elucidate the differences between Pi transport data obtained by two widely used Pi 
uptake methods, the in vitro everted sleeve technique and the in situ intestinal closed-
loop technique.   
 
McHardy et al established that intestinal luminal Pi concentrations were in the millimolar 
range [201] however, the Kt of intestinal NaPi-IIb has been measured to be around 
0.1mM.  Thus, most studies to date have also utilized a range of low Pi concentrations 
in order to assess the contribution of NaPi-IIb activity specifically.  Present experiments 
utilized three concentrations of Pi (0.1, 1, and 10mM) to study Pi transport in five 
intestinal regions.  It has been shown that Pi uptake observed using the everted sleeve 
remained linear after a 1 min exposure of the everted tissue segment to uptake buffer 
[200]; for that reason a 2 min uptake time was chosen as an estimated midpoint of 
linear Pi uptake.   The in situ closed-loop technique has also been validated in the 
context of Pi transport [12].  Results of the present study indicated that Pi 
concentrations up to 10mM caused a corresponding rise in the rate of Pi absorption 
both in vitro and in situ  (Figure 2.3 and 2.4).  The jejunum is the region with the 
highest rate of Pi measured using both techniques, which corresponds appropriately 
with previously published data of mRNA and protein expression [17, 62] 
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In terms of overall Pi transport ability, the in situ results using the ileum stand out from 
previously published data.  Although the ileum does not transport Pi as effectively as 
the proximal small intestine (duodenum and jejunum), it exhibits significant transport 
ability compared to the colon.  In contrast, the ileum transports the least amount of Pi in 
vitro (Figure 2.7).   These differences seen between the in situ and in vitro data may be 
explained by referring to the time that intestinal contents spend in the different regions.  
Chyme remains in the ileum for the longest period of time compared to other segments 
of the GI tract (~2-3 hours) [202].  In this instance, the in situ method may more 
accurately represent the total accumulated amount of Pi transported, as plasma Pi 
measured in these experiments were taken after a 30 min period instead of 2 min used 
for  uptakes using the everted sleeve.   
 
There has been an increase in frequency of observations of hyperphosphatemia 
following phosphate-containing enemas, first published in 1977 [203].  When presented 
with a constant Pi source in flux (in vitro), the distal colon surprisingly transports almost 
as much Pi as the small intestine.  Compared with the in situ distal colon data presented 
however, this mechanism of Pi transport has no sodium-dependency at any Pi 
concentration. Therefore, the colon epithelium may simply be more permeable to 
solutes (i.e. “leaky”) as prior studies show that there is relatively little unbound Pi at this 
point of the rat GI tract. [200].  If the amount of unbound Pi in the large intestine is 
negligible, the Pi transport mechanisms revealed in present studies may not actually 
occur under physiological conditions.  There may, however, be a mechanistic 
importance of Pi transport in the distal colon as short chain fatty acids, which are in 
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abundance in the colon, may displace small amounts of Pi from anion exchanger sites 
in distal colon [204] - this occurrence makes Pi available for absorption.  Ultimately, 
whether Pi transport in this region has any significance to overall Pi homeostasis 
remains unclear.   
 
Discrepancies were seen in sodium-dependent Pi transport data between the two 
techniques (Figure 2.7).  Apart from the jejunum and proximal colon, which exhibit 
sodium-dependency and no sodium-dependency respectively across all concentrations 
utilized, all other intestinal segments had varying results.  Data from in vitro sodium-
dependent Pi transport in the duodenum may be due to the pH of buffer, favoring more 
NaPi-IIb transport activity than PiT1.  pH affects the proportion of two different Pi anions 
in solution (refer to section 1.2.1.3), with NaPi-IIb transporting the dilvalent form which is 
in abundance at a more neutral to basic pH;  buffers used in present experiments were 
adjusted to this physiological 7.4 pH. [61].  Both NaPi-IIb and PiT1 proteins however, 
are not highly expressed in the duodenum [17], thus the overall Pi contributions of either 
may be negligible.  Intestinal pH variations may also explain the data differences 
between these two techniques in the other intestinal regions that were investigated in 
these studies.  The proximal small intestine starts off relatively acidic at the duodenum 
(pH of 5.5-6) and increases to an almost neutral state in the distal ileum since microflora 
become more abundant in these latter regions [205].  All solutions used in uptake 
experiments were adjusted to a pH of 7.4, thus PiT transporters which may function at a 
higher capacity in an acidic pH environment may not have been operating at full 
physiological capacity [61].     
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Interestingly, data from in situ experiments show a lack of sodium-dependency for 
duodenal Pi transport.  This distinct contrast could reflect widely varying intestinal 
luminal transit times in difference regions of the intestine, with ingested food not 
remaining in the duodenum for as long as in the jejunum/ileum [202].  In this regard, the 
in vitro everted sleeve technique may be a representative model for duodenal Pi 
transport since transit time for chyme in rat duodenum is approximately 2 min.  
 
 
 
Figure 2.7.  Summary of the main differences in Pi uptake seen using in vitro and in situ 
techniques 
Black text refers to sodium-dependency of the region, lighter text compares magnitude of Pi transport 
between regions examined using the same method. 
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The Pi transport data obtained using the everted sleeve technique accurately reflects 
the rate of Pi taken up by the intestinal epithelium (i.e. BBM transport), however it does 
not represent the Pi transfer across the epithelium.  In this respect, the in situ loop 
method gives a more complete picture since it reflects Pi transfer from lumen to blood.  
The differences in the rate of Pi transport using the two techniques (higher amount of Pi 
transported utilizing in vitro technique) correlates with this difference in the way Pi 
uptake is measured; the everted intestinal tissue is constantly exposured to a moving 
(stirred) Pi sample, while the in situ loop technique’s Pi transport is measured as Pi 
transported to the blood circulation.  The Pi buffer utilized in the in situ method is less 
well-mixed compared with that in intestinal closed loops, and thus less Pi may be 
continuously exposed to the epithelium since Pi transport depletes the Pi at the 
epithelial surface.   
 
The amount of total Pi transported in both in vitro and in situ techniques is minimal (less 
than 0.5% of the Pi in initial Pi buffer taken up by all segments across both methods), 
thus differences between methods and segments may not have significant impact on 
overall Pi homeostasis under normal conditions.  However, it is important to note that in 
the context of kidney disease and reduced renal function, these minute differences in 
intestinal Pi handling can have greater effect on blood Pi levels.   
 
It is known that claudins control tight junctions and their selective permeability to 
solutes, however their role in regulating Pi transport across the small intestine is 
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unclear.  Claudin-1, 3, 4, 5, and 8 form paracellular barriers and contribute to “tight” 
epithelia while other claudins such as claudin-2 , 7 and 12 form paracellular cation 
channels (pore-forming claudins) and mediate paracellular ion transport [206-209].  The 
rat jejunum has been shown to express claudin-5 and 12 which permit ion permeability, 
whereas the duodenum expresses the claudins associated with “tightening” of the 
epithelia, claudin-1, 3, 4, and 8 [210, 211]. This difference in claudin expression 
between the duodenum and the jejunum may explain the reduced Pi transport in the 
duodenum compared with the jejunum.  The expression of claudin 5 and 12 in the 
jejunum would theoretically increase paracellular ion permeabitliy and potential 
paracellular Pi transport.  However, it is clear from the data in this chapter that 
paracellular Pi transport in the jejunum is not the dominant form of Pi transport; NaPi-IIb 
is highly expressed in this region and sodium-dependent Pi uptake is seen across all 
concentrations of Pi used to study Pi uptake in this region (Figures 2.3 and 2.4).  The 
colon has been shown to exhibit high expression of the “tightening” claudins, claudin-1, 
3, 4, 5, 8 [211].  Data show that the distal colon transports a notable amount of Pi, 
which has previously never been thought to be a site of significant Pi transport (Figure 
2.5), thus expression of NaPi-IIb, PiT1, and potentially a novel Pi transporter should be 
studied in the future.  Interestingly, claudin-2 and claudin-12 act as paracellular Ca2+ 
channels in the small intestine and their expression has been recently shown to be 
upregulated by a known Pi regulator, vitamin D [212]; no anion-selective claudins have 
been analyzed to date to see if they are capable of transporting the Pi anion.  It would 
be interesting to attribute sodium-independent Pi transport to changes in claudin 
expression following Pi exposure.  
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It is essential to link changes in Pi transport to protein levels of tissue-specific Pi 
transporters.  Several commercial antibodies are available for detection of NaPi-IIb 
protein in mice, however no antibodies thus far have been shown to recognize the rat 
isoform.  Colleagues have tested a number of rat-specific NaPi-IIb antibodies on 
positive control rat tissues (e.g. lung brush border membrane [14, 213]) with none of the 
antibodies detecting consistent NaPi-IIb protein.  Therefore, it has not been possible to 
directly correlate Pi transport data in the different regions of the rat intestine examined 
in this chapter with altered levels of NaPi-IIb protein.     
 
Importantly, EM analysis indicates that intestinal ultrastructure is not compromised in 
either of the two techniques, and differences in Pi transport therefore did not represent 
diffusion across a damaged epithelium.  In EM images, the tight junctions and intestinal 
villi remain unaffected by manipulation of tissue using both methods and across all 
segments of intestine utilized.  Differences in the magnitude of Pi transport and sodium-
dependency are thus attributed to other mechanisms that have not been explored at 
present. 
 
2.4.1.  Summary and conclusion 
Data using in vitro and in situ techniques for measuring Pi transport indicate that the two 
methods can produce considerably different results.  Direct comparisons of techniques 
have not been previously explored, and the importance of knowing what each specific 
technique accurately represents, and act as an appropriate model for, is emphasized in 
these studies.  Data obtained confirm the jejunum to be the region with the highest Pi 
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transport capacity.  Novel data was observed using the distal colon, since this region 
was shown to display significant Pi transport ability.  It can be concluded that for some 
aspects of Pi transport in specific regions (e.g. duodenum) the everted sleeve method 
may be a more accurate representative of physiological acivity, whereas studying 
intestinal regions where luminal contents may remain for a longer period of time (distal 
small intestine and large intestine) may warrant the use of other methods such as the in 
situ closed-loop technique.  These results may provide insight into how different regions 
of the GI tract can be targeted to regulate Pi transport in instances of altered body Pi 
balance, for example the hyperphosphatemia in chronic renal failure.   
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3.0.  Measuring Pi transport across the rat intestinal epithelium 
using an ex vivo intestinal preparation 
 
 
3.1.  Introduction 
 
As shown in the previous chapter, many discrepancies are seen between Pi transport 
data obtained from in vitro and in vivo methods.  Mainly, these two methods measure 
different pathways of Pi transport - the in vitro everted sleeve method detects the 
amount of Pi that is taken up at the intestinal brush border and retained within 
enterocytes while the in vivo intestinal closed-loop method reflects the amount of Pi that 
is both transported from the intestine into blood circulation and that retained within the 
mucosa.  While both methods have contributed to the basis of our current 
understanding of Pi transport, they leave gaps in information.    
 
Discovering new treatments for hyperphosphatemia in the framework of chronic kidney 
disease (CKD) first involves elucidating the mechanisms of Pi transport across the 
intestine.  Numerous studies have shown that the regional profile for intestinal Pi 
absorption is different across species such as between rats and mice, although the 
mechanisms behind this are still unclear. In rats and humans, the highest rates of 
transport occur in the duodenum and jejunum [133], whilst in mice maximal absorption 
occurs in the ileum. In both rats and mice, the profile of absorption is paralleled by 
levels of NaPi-IIb mRNA and protein, the main sodium-dependent Pi transporter in the 
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intestine [12, 54, 62].  Studies using conditional tamoxifen-inducible NaPi-IIb-/- KO mice 
have shown that this protein is responsible for ~90% of sodium-dependent transport 
across the mouse ileum BBM.  It has also been revealed that the transporter accounted 
for only ~50% of total intestinal transepithelial Pi absorption in response to a dietary Pi 
load [54]. This finding confirms the early observations of a significant sodium-
independent component of intestinal Pi transport [133, 136], although it is still unclear 
as to whether sodium-independent transport occurs via a transcellular or paracellular 
route.   
 
Paracellular Pi transport forms a component of the sodium-independent Pi transport, 
however the way in which this pathway is regulated, perhaps via tight junction proteins 
such as claudins, is unknown.  Concurrently, the exit path of Pi at the basolateral 
membrane of enterocytes has not been characterized and a potential Pi transporter 
could exist in this region.  Introducing an ex vivo method that has never been applied to 
investigate Pi transport would shed light on the mechanisms of Pi transport by 
observing the composition of contents directly transferred across the serosal side of the 
intestine without the complication of dilution in systemic blood.     
 
Fisher and Gardner established a technique in 1974 in which the transport of solutes 
across intact epithelium could be quantified [214].  In the ex vivo intestinal perfusion 
method, a segment of the intestine is removed from the animal and perfused with 
bicarbonate buffer interspersed with O2/CO2.  These alternating gas and perfusate 
buffer “slugs” maintain efficient oxygenation of the mucosa which contributes towards its 
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viability [214].  The resulting fluid that is transferred to the serosal side of the intestinal 
segment can be collected at intervals and analysed for its composition.  The technique 
has been successfully employed to measure the absorption of flavonoids, olive oil 
polyphenols, clinical drugs, and glucose [215-219].  The advantage of this method in 
investigating Pi transport is that that the amount of Pi obtained from the serosal fluid 
can be interpreted as the amount directly passing through the tissue as a whole, 
whereas in vitro and in vivo techniques only measure Pi uptake at the BBM or the 
appearance of solute in the blood respectively.  The concentration of Pi contained in the 
serosal fluid of the perfused ex vivo intestine model can therefore be directly compared 
with the Pi concentration contained in the perfusate buffer.  This specific ex vivo method 
has not been used to investigate Pi transport across the intestinal epithelium.    
 
3.1.1.  Aims of this study 
1.  To compare Pi transport across the jejunum and ileum of rats utilizing the ex vivo 
intestinal perfusion technique.  Investigate sodium-dependent Pi transport across the 
jejunum and ileum by using choline chloride (ChCl)-based to replace sodium chloride, 
NaCl in perfusate for a portion of the experiment.    
 
2.  Analyze serosal fluid to assess whether concentration of Pi during the transport 
process across the intestinal epithelium is achieved. 
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3.2.  Materials and Methods 
 
3.2.1.  Animal Model 
Male Sprague Dawley (SD) rats between 250g-300g were obtained from Charles River 
Laboratories (UK) and used in accordance with the Animals (Scientific Procedures) Act 
1986.  Rats were allowed ad libitum access to standard rodent chow containing 0.52% 
phosphate (Diet RM1, SDS Ltd, Witham, Essex UK) and water.  
 
3.2.2.  Ex vivo intestinal perfusion 
Rats were weighed then anesthetized by an IP injection of pentobarbitone sodium 
(45mg/kg body weight).  Body temperature was maintained at 37oC using a heating pad 
during sequential removal of intestinal sections.  
 
A midline incision was made and 10-15 cm of intestinal tissue was isolated (jejunal 
segments began at the ligament of Treitz and ileal segments ended at the cecum).  
These sections were tied off with ligatures and incisions were made at either end of the 
section.  Warmed saline was flushed through the segment to remove any food debris 
followed by air to remove as much luminal fluid as possible.  Following this, silicone 
tubing was secured to both ends of the intestine with additional ligatures.  One tube 
delivered a perfusate consisting of a segmental flow of 95% O2/5% CO2 interspersed 
with a Krebs bicarbonate solution (25mM HCO3, 143mM Na, 133.7mM Cl, 5.9mM K, 
1.2mM HPO4, 2mM Ca2+, 1.2mM Mg2+ , pH 7.4) containing 10 or 28mM glucose added 
fresh before every experiment.  Using a rotary pump, the rate of perfusion was adjusted 
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to approximately 1 mL per minute.  The tube at the distal end of the intestine served to 
deliver the effluent into a waste container.  In experiments studying sodium-independent 
Pi transport, NaCl was substituted with ChCl and NaHCO3 was substituted with choline 
carbonate (ChHCO3).  Once the effluent appeared, the intestinal segment was then 
removed from the animal by stripping it from the mesentry and then suspending it in 
37oC liquid paraffin (specific gravity 0.83-0.86) (Figure 3.1).  The animal was then 
sacrificed following the removal of the last intestinal segment.  Segmental flow was 
maintained throughout the procedure with a 40 minute equilibration period to flush blood 
from the vasculature and for transport to reach a steady state.  Serosal fluid collections 
were made at 20 and 40 min post equilibration.  Studies examining the effect of sodium-
free buffer included a further 40 minutes of perfusion with the sodium-free buffer as well 
as another 40 min switch back to the sodium-containing buffer.  Serosal fluid collections 
were centrifuged at 6000 rpm for 10 min at 4oC and serosal fluid was removed with a 
14g needle from under the paraffin layer collected with serosal fluid.   
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Figure 3.1. Diagram of the ex vivo intestinal perfusion method 
 
 
3.2.3.  Determining Pi and glucose concentrations 
Pi and glucose concentrations were measured in the serosal fluid using a commercially 
available Pi assay kit (Quantichrome DIPI-500, USA) and a colorimetric glucose assay.  
The latter works on the principle that glucose contained in the serosal fluid is oxidised 
by a glucose oxidase reagent (GOR) containing glucose oxidase, peroxidise, and 
dianisine.  Oxidation of glucose produces hydrogen peroxide which, in the presence of 
peroxidase, oxidises dianisidine in the reagent to produce a colorimetric response 
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(oxidised o-dianisidine) which can be measured using a spectrophotometer at a 450nm 
wavelength.  The GOR was prepared with 44 mg glucose oxidase, 1.76 mL peroxidase 
(from a 0.53 mg/mL stock) and 2.8 mL dianisidine (from a 2.5 mg/mL stock) diluted in 
176 mL dH2O.  Glucose standards were then prepared for 5, 10 and 15 mM glucose 
added to 500 μL dH2O and 4 ml GOR.  Samples were also added to 500 μL dH2O with 
4 mL GOR and incubated for 1 hour at room temperature.  Duplicates of samples and 
standards were measured at 450 nm with a Beckman Du650 spectrophotometer 
(Beckman-Coulter Research, Buckinghamshire, UK). 
 
3.2.4.  Statistical analysis 
Data is presented as mean ± SEM.  A student’s paired t-test or a one-way ANOVA, as 
appropriate, was used and group differences were stated as statistically significant if P 
< 0.05; n represents the sample size of each experiment.  Glucose and Pi 
concentrations were first plotted relative to perfusate concentrations, followed by an 
absolute (nmole) quantity transported per cm of intestinal tissue per min.  Nanomole 
values of glucose and Pi were obtained by taking into account the overall serosal fluid 
volume collected at each 20 min time point.   
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3.3.  Results 
 
3.3.1.  Pi transport across the rat intestinal epithelium 
Serosal fluid was collected 20 min and 40 min post equilibration period.  The fluid was 
then utilized to determine Pi and glucose concentration.  The concentration of glucose 
and Pi in the serosal fluid was analyzed using a Student’s t-test relative to the 
perfusate.  A significant increase was seen in glucose concentration using jejunum at 
both 20 and 40 min post equilibration, but not using ileum (Figure 3.2).  Pi 
concentrations in the serosal fluid collected from jejunal and ileal segments were both 
significantly higher than the 1.2mM present in the perfusate at both time points (Figure 
3.2). 
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Figure 3.2. Glucose and Pi concentrations in serosal fluid 
Values were analyzed for statistical significance using a Student’s t-test (compared to the 
concentrations found in perfusate as indicated by “buffer in”) * denotes P < 0.05, ** = P< 0.01, 
*** = P < 0.001 with n = 5. 
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3.3.2.  Pi transport across the intestinal epithelium during sodium switching 
Sodium-dependent Pi transport was analyzed using a perfusate switch protocol.  In 
these experiments, normal perfusate was used and two collections of serosal fluid were 
made at 20 and 40 minutes post equilibration as described previously.  Following this, a 
“sodium-free” buffer in which NaCl was substituted with ChCl and NaHCO3 was 
substituted with ChHCO3 was perfused through the segment and two collections of 
serosal fluid were made 20 and 40 min following the switch (represented by Ch-20min 
and Ch-40min).  Normal, sodium-containing bicarbonate buffer was then reintroduced 
for 2 further serosal fluid collections at 20 and 40 min (Na-20min2 and Na-40min2).    
 
Data for glucose concentration shows a significant increase following reintroduction of 
sodium-containing buffer in the last 40 minutes of the experiment in jejunal segments 
(Figure 3.3a).  Interestingly, there was a significant decrease in glucose concentration 
at all time points using the ileum (Figure 3.3a).  Data for Pi concentration shows that 
there is concentrated Pi in serosal fluid at all time points for both the jejunum and the 
ileum (Figure 3.3a). 
 
When glucose and Pi are expressed as nmole transported relative to intestinal segment 
length and time, a significant decrease is seen in glucose transport across the jejunum 
between 20 and 40 min after sodium-free buffer (Ch) is introduced (Figure 3.3b).  
There is also a significant reduction in Pi transported between 20 and 40 min after 
sodium-free buffer is introduced in both jejunum and ileum (Figure 3.3b).  There is a 
significant increase in Pi transported between 20 and 40 minutes after reintroduction of 
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normal, sodium-containing buffer in both segments of intestine (Figure 3.3b).  A similar 
pattern is seen when considering the volume of serosal fluid absorbed across the 
epithelium (Figure 3.3c).   
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Figure 3.3a.  Glucose and Pi concentrations in serosal fluid after switching between 
sodium containing and sodium-free perfusate buffers containing 28mM glucose 
There is an approximate 2-3x increase in Pi concentration, with a variable glucose 
concentration seen.  The only significant increase in glucose concentration appeared in the last 
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20 minutes of experiments utilizing jejunal segments.  * denotes P < 0.05, *** = P < 0.001.  n = 
7 
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Figure 3.3b. Glucose and Pi transport expressed per cm of intestine per minute using 
28mM glucose in perfusate 
A significant drop in glucose transport is seen after switching to a sodium-free buffer between 
20-40min in the jejunum only.  A significant decrease in Pi occurred after switching to sodium-
free buffer between 20 and 40 minutes as well as a significant increase following reintroduction 
of sodium containing buffer.  * denotes P < 0.05, ** = P< 0.01.  n = 7 
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Figure 3.3c. Volume of serosal fluid collected per cm of intestine per minute using 28mM 
glucose in perfusate 
There is a significant change in fluid transport 20-40 min after the switch to a sodium-free 
perfusate in both the jejunal and ileal segments.  There is also a significant change between 
20-40 min after the switch back to a sodium containing buffer.  * denotes P < 0.05, ** = P< 
0.01.  n = 7 
     
 
 
 
 
 
3.3.3.  Pi transport across intestinal epithelium during sodium switching (using 
10mM glucose) 
10mM glucose was utilized in these experiments as opposed to 28mM glucose in order 
to observe changes in total serosal volume and whether this change affected the 
increase in Pi concentration seen in previous experiments (Figures 3.2 and 3.3a).  The 
protocol was identical to that described in the section above. 
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Data for glucose concentration in the serosal fluid shows a significant decrease 
compared to the perfusate concentration of 10mM in both jejunal and ileal segments 
(Figure 3.4a).  Data for Pi concentration shows that there is significantly higher 
concentration Pi collected at the serosal side at all time points for both jejunal and ileal 
segments (Figure 3.4a). 
 
When glucose and Pi data is expressed as quantity transported relative to intestinal 
segment length and time, a significant drop was seen in glucose transported in the 
ileum between 20 and 40 min after introduction of sodium-free buffer (Ch) (Figure 
3.4b).   There is a significant increase in glucose transported across the jejunum 20-40 
min after sodium-containing buffer is reintroduced.  There is a decrease in Pi 
transported between 20 and 40 min after sodium-free buffer is introduced and also an 
increase in Pi transported when sodium-containing buffer is reintroduced in both the 
jejunum and ileum (Figure 3.4b).  In addition to this pattern, there is a significant 
increase in Pi transported between 20 and 40 min in the ileum at the start of this 
experiment.  This increase in Pi transport at the beginning could be attributed to an 
obstruction in the luminal space of the intestine (either by a twisting of the intestine, or 
by luminal contents which were not completely removed during initial preparation of the 
segment). This might have delayed transport equilibrium.   A decrease in serosal fluid 
volume following removal of sodium in the buffer and subsequent increase of  fluid 
volume following reintroduction of sodium is also seen in these experiments (Figure 
3.4c).     
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Figure 3.4a. Glucose and Pi concentrations in serosal fluid after switching between 
sodium-containing and sodium-free perfusate containing 10mM glucose 
Both jejunal and ileal segments show no increase in glucose concentration.  Pi concentrations 
were all significantly higher compared to the perfusate.  ** denotes = P< 0.01, *** = P < 0.001.  
n = 7 
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Figure 3.4b. Glucose and Pi transported per cm of intestine per minute using 10mM 
glucose in perfusate 
A significant drop in glucose and Pi are seen after switching to sodium-free buffer between 20 
and 40 minutes.  Similar changes were seen with Pi, with a significant drop and rise occurring 
20-40min following switch to sodium-free buffer and switch back to normal buffer respectively.  
* denotes P < 0.05, ** = P< 0.01, *** = P < 0.001.  n = 7 
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Figure 3.4c. Serosal fluid volume per cm of intestine per minute using 10mM glucose in 
perfusate buffer 
There is a significant decrease in fluid passing through the epithelium 20-40 minutes after the 
switch to a sodium-free perfusate buffer in both the jejunal and ileal segments.  There is also a 
significant increase between 20-40 min following the switch back to a sodium containing buffer.  
* denotes P < 0.05, ** = P< 0.01, *** = P < 0.001.  n = 7 
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3.4.  Discussion 
 
Results from this chapter demonstrate a novel application of the ex vivo intestinal 
perfusion technique to measure transport of Pi across the intestinal epithelium.  
Previous in vivo and in vitro methods have interpreted the amount of Pi transported by 
the intestine as the increase in concentration of Pi appearance in the blood or the 
amount of Pi taken up by everted intestinal tissue.  While both of these methods have 
helped to form our current understanding of intestinal Pi transport, their pitfalls stem 
from the fact that the amount of Pi directly transported across the epithelium is not 
represented.  Here, it is shown for the first time that there is a concentration of Pi during 
its transport across the intestinal epithelium, and thus a proof of principle that active 
transport of Pi is taking place.    
 
The initial experiments which utilized a standard Kreb’s buffer (containing 1.2mM Pi) 
show concentrated Pi in the serosal fluid (approx 2-3x higher compared to perfusate Pi 
concentration).  To further show that there is a significant, active, mostly NaPi-IIb 
regulated Pi transport process in the intestine, additional experiments were conducted 
using a period of sodium-free conditions in the perfusate (ChCl and ChHCO3 replacing 
NaCl and NaHCO3 respectively).  When utilizing both 28mM and 10mM glucose in the 
perfusate, significant changes in Pi transport are seen following the switch to sodium-
free buffer (between 20-40min) as well as following the switch back to a sodium-
containing buffer (also between 20-40min after the switch) (Figures 3.3b and 3.4b).  It 
is speculated that the lag-time in response to switching between the perfusates 
(approximately 20 min) seen in the present experiments represents transport reaching 
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equilibrium.  Unlike the 40 minute equilibration period prior to collection of the first 
sample of serosal fluid, no equilibration period is allowed following the switch to sodium-
free buffer and the switch back to sodium-containing buffer.  Thus the serosal fluid 
collected during the 20 minutes following this switch may partially represent the Pi 
transported in the presence of sodium buffer.   Additionally, the concentration of Pi 
measured in serosal fluid could not be attributed to contamination with liquid paraffin 
since a liquid paraffin control was assayed for Pi to determine if it contained substantial 
Pi concentration that may have affected the results.   From this data, we can conclude 
that sodium-driven transport of Pi is indeed taking place in both the jejunum and the 
ileum.   
 
Glucose is included in the perfusate buffer as it acts as a metabolic substrate for 
intestinal tissue and contributes to tissue viability [220].  It drives water transport across 
the intestinal epithelium in order to produce sufficient serosal fluid for analysis.  Water 
transport across the epithelium occurs mainly via aquaporin channels (e.g. aquaporin 5 
which is specifically expressed in the stomach and duodenum [221]), however the 
intestinal glucose transporters, SGLT1, GLUT1, and GLUT2 also function as a gateway 
for transepithelial water transport [222-224]. When comparing experiments using 28mM 
and 10mM of glucose in the perfusate buffer however, it is evident that serosal fluid 
volumes are relatively similar.  This may suggest that SGLT1 and the aquaporins 
expressed in the jejunal and ileal segments used in these experiments function at the 
same water transport capacity in the presence either 10mM or 28mM glucose.  Future 
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studies could investigate a glucose concentration that would affect transepithelial water 
transport by using lower amounts of glucose in the perfusate buffer.   
  
Previous studies show an ex vivo intestinal tissue viability timeline of upwards of 120 
min following removal from the blood supply [214, 225].  Viability was mainly 
determined by observing a constant, active transport component of glucose.  It is of 
note that in the present experiments, there is inconsistent glucose transport - 
specifically, there is an apparent  lack of active glucose transport across the ileum using 
28mM glucose in the perfusate as well as in both jejunum and ileum at 10mM glucose.  
Accumulative glucose transport has always been a hallmark of the ex vivo perfusion 
technique, and this raises concerns about tissue viability in the present experiments.  
One explanation for lower than expected glucose concentration in the serosal fluid 
revolves around possible distension of the intestine during the perfusion period, which 
could stretch and damage the intestine and potentially impair solute transport 
mechanisms.  Another factor that may contribute to inconsistent glucose transport in the 
intestine is buffer perfusion rate.  The rate implemented using this technique varies 
widely, with published methods anywhere in between 0.5 - 7mL/min [225-227].  A flow 
rate of 1 mL/min was used in the current experiments since this was found by previous 
work to be the best choice to minimize perfusate build-up in the loop of intestinal 
segment, which could lead to distension and damage to intestinal tissue [228].  The 
present data shows that following the switch from sodium-free perfusate back to 
sodium-containing perfusate there was a trend for an increase in glucose transport 
(Figures 3.3b and 3.4b).  This pattern of increased glucose transport upon 
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reintroduction of sodium-containing perfusate towards the end of the experiment, along 
with the sustained Pi transport observed, support the fact that the intestinal tissue is 
intact and viable.   
 
Intriguingly, there is an absence of sodium-dependence of glucose transport in the 
ileum while utilizing perfusate containing 28mM glucose (Figure 3.3b).  The reason for 
a lack of sodium dependency could involve the use of 28mM glucose, as the sodium-
dependent transporter SGLT1 has been shown to have a Km of around 0.2-0.5mM [229, 
230], thus SGLT1 and sodium-dependent glucose transport would function maximally in 
the presence of lower luminal glucose concentrations.  The intestinal facilitative glucose 
transporter, GLUT2, which does not require sodium for glucose transport, has a high Km 
of 17mM for glucose [231] and is shuttled to the apical membrane of the intestine in 
response to high luminal glucose concentrations [232]. Indeed when utilizing 10mM 
glucose (Figure 3.4b), sodium-dependent glucose transport is seen in both the jejunum 
and the ileum following switches between the two different perfusate buffers.  The 
serosal fluid volume for experiments using 28mM glucose show significant changes in 
response to sodium-free buffer switching and reintroduction (Figure 3.3c), thus the lack 
of sodium dependency in glucose is not inhibiting water transport.   
 
Serosal fluid collected from perfusion experiments conducted by colleagues utilizing 
mouse proximal small intestine show a concentration of glucose in the serosal fluid 
(personal communication).  Glucose transporter expression and adaptation in response 
to changes in luminal glucose in the intestine may thus differ between species.  SGLT1 
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is known to be expressed mainly in mature enterocytes across most species; however, 
mouse and rat glucose transporters are shown to have different characteristics.  
Phlorizin, a competitive inhibitor of SGLT1 has different inhibition constants between 
species (rat and rabbit) [229, 233].  GLUT2, although responsible for apical glucose 
transport only at high luminal concentrations, has been shown to have approximately 
81% homology between human, rat, and mouse [234] and its expression level is 
different between humans and mouse in pancreatic ß-cells [235].  This potential 
difference in expression between species, in addition to the lower perfusion rate utilized 
in the present experiments as compared with those described in the original publication 
of the method [214, 220], may explain why concentrated glucose was not seen in the 
serosal fluid of perfused rat intestine in the present experiments.   
 
It has recently been shown that there are morphological changes in the intestine 
following induction of CKD in rats - these changes occur along the tight junctions 
between enterocytes of the intestinal epithelium and mimic changes that occur following 
damage to the epithelium [137].  Specifically, these studies show that there are 
alterations in protein levels of claudin-1 and occludin, key constituents of tight junctions 
in intestinal epithelia in rat models of CKD [138].  Since tight junctions may serve 
important regulatory functions in the still uncharacterized sodium-independent Pi 
transport pathway, these anomalies in expression of tight junction proteins need to be 
investigated further to elucidate consequences for intestinal Pi transport in the context 
of CKD.  Disturbances in the architecture of tight junctions may, in turn, passively 
release more solutes into the bloodstream perhaps in an unregulated manner.   
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Interestingly, mutations in genes encoding for claudin-16 produce phenotypes of 
hypomagnesemia with hypercalciruria [236-238], changes that may be related to the 
mechanisms of hyperphosphatemia seen in CKD.  Future experiments could involve 
utilizing the ex vivo perfusion method using intestinal tissue from CKD-induced rats and 
comparing results between control and CKD animals.   
 
Importantly, data shown in this present work illustrate that the ex vivo intestinal 
perfusion technique could provide important information regarding the transport of Pi.  
Serosal fluid could be analyzed in the future to see if this contains factors that are 
dependent on the level of Pi in luminal fluid.  The composition of the serosal fluid would 
shed light on if and how the intestine signals to other organs, such as the kidney, in 
response to an acute dietary Pi load.  Revealing these intestinal-derived Pi signalling 
mechanisms will contribute towards discovering new targets for control of body Pi 
balance in the context of CKD.   
 
3.4.1.  Summary and conclusion  
The ex vivo intestinal perfusion technique reported by Fisher and Gardner in 1974 has 
not been utilized to date in furthering our understanding of Pi transport across the rat 
intestine.  In the present experiments, this perfusion method has been used to show 
that there is a significant increase in the concentration of Pi in fluid absorbed across the 
rat intestinal epithelium.  The significant reduction in Pi transport following a switch to 
sodium-free perfusate also points to an active transport mechanism most likely 
attributed to NaPi-IIb at the BBM, although the mechanism of Pi transport at the 
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basolateral membrane has not been characterized.  These results further our overall 
knowledge of Pi transport across the rat intestine and validate the ex vivo perfusion 
method for future studies involving Pi transport.   
Chapter 4 
 
 
122 
4.0.  The effect of a duodenal Pi load on urinary Pi excretion and 
renal phosphate transporter expression 
 
 
4.1.  Introduction 
 
Communication between the small intestine and the kidney has been established in 
regulating such solutes as sodium, calcium and potassium (comprehensive review in 
[239]).  For example, body sodium homeostasis has been theorized to depend, at least 
in part, on crosstalk between these two organs. The intestine is known to produce 
circulating peptides called guanylin and uroguanylin which are important for natruiresis 
[240, 241].  Calcium-sensing receptors are also found in both the epithelium of the 
intestine and the kidney as these receptors play a large role in calcium, Pi and amino 
acid homeostasis [242-244].   
 
With the recent emphasis on the correlation of high serum Pi with cardiovascular events 
in CKD, it is now becoming apparent that new methods of detecting and treating 
hyperphosphatemia are needed.  A present concern involves high Pi preservatives in 
food possibly lending to overall Pi toxicity.  While only 40-60% of naturally occurring 
dietary Pi is thought to be absorbed, inorganic Pi from preservatives has a higher 
bioavailability [120].  Their presence can also increase the Pi content in food by as 
much as 70% [245], thus preservatives have the potential to significantly impact 
postprandial Pi load.  A recent study showed that following ingestion of Pi salts 
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commonly found in additives, serum Pi levels increased for a period of up to 20 hours 
[246].  
 
In 2007, Berndt et al demonstrated that instillation of a high concentration of sodium Pi 
(1.3M) into the proximal small intestine increased urinary Pi excretion in less than 30 
min [139, 140].  This acute effect did not occur following a duodenal instillation of saline 
nor was an increase in urinary Pi excretion seen following a Pi load directly into the 
stomach.  This observation pointed to a specific Pi signalling process occurring in the 
upper small intestine which was independent of known regulators of Pi such as PTH, 
FGF-23, sFRP-4, changes in GFR, or the involvement of a kidney neural reflex as 
demonstrated by experiments on rats with denervated kidneys.  Additionally, Berndt 
showed that IV infusion of an extract prepared from the duodenal mucosa also had an 
overall phosphaturic effect.  Importantly, no changes in plasma Pi levels were seen in 
any of these procedures suggesting that, if there was indeed some type of intestinal Pi 
sensing factor, it acted independently of changes in plasma Pi levels.   
 
One main area of concern in these studies by Berndt et al involved the concentration of 
Pi utilized in renal clearance experiments – an erratum which was subsequently 
published stated that 1.3M Pi instead of 1.3mM Pi was utilized in the studies [140].  Pi 
concentrations in the molar range do not represent physiological concentrations and the 
results may have been due to changes in the structure of the intestine in response to 
the high osmolality of the infused buffer. 
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The consequences of a potential intestinal signalling pathway for Pi are potentially far 
reaching, especially for CKD patients. Due to declining renal function in CKD, targeting 
the kidney to attenuate hyperphosphatemia becomes difficult.  The small intestine on 
the other hand, may be a suitable target for treatment since intestinal Pi absorption 
does not seem to be significantly altered in animal models of CKD [117].  It is therefore 
vital to elucidate the mechanisms of Pi transport following an acute Pi load into the 
intestine since the intestine could be a target for treatment in clinical 
hyperphosphatemia.   
 
4.1.1.  Aims of this study 
1.   To replicate Berndt et al (2007) in vivo experiments with a physiological duodenal 
load of 10mM Pi as well as the 1.3M concentration that the group utilized [139, 140].   
 
2.  To examine protein expression of renal NaPi-IIa and NaPi-IIc of animals utilized in 
these experiments. 
 
3.   Place rats on a chronic low Pi diet and repeat experiments described in aim 1 to see 
if low Pi diet priming is needed to illicit a (greater) sodium-cotransporter protein 
expression response to an acute duodenal Pi load [62]. 
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4.2.  Materials and methods 
 
4.2.1.  Animal model  
Experiments were performed on male Sprague Dawley rats 12–14 weeks old (250-
300g).  Animals were given free access to water and standard commercial rat chow 
(Diet RM1, 0.52%  Pi, Special Diet Services, UK) or low Pi diet, containing 0.1% 
phosphorous by weight (Special Diet Services, UK) and were maintained under 
controlled conditions of temperature and light.  
 
4.2.2.  Renal function in anesthetized rats 
Sprague Dawley rats were either fed a normal diet as mentioned above, or primed with 
a diet of low Pi (0.1% Pi SDS diet #120426.16) over a full 7-day period before 
experiments took place.  Rats were then anaesthetized by IP injection of 
thiobutabarbital (Inactin, 120 mg/kg; Sigma Aldrich UK).  Unlike other anesthetics such 
as pentobarbital, thiobutabarbital has been shown to provide a more stable, long term 
analgesic effect in rats measured by stable GFR [247, 248].  A series of surgical 
procedures then took place: tracheotomy to maintain a clear airway, femoral artery 
cannulation for blood collections and mean arterial blood pressure (MAP) monitoring 
utilizing a blood pressure monitor (Adinstruments MLT0380/D, Powerlab 500 software, 
UK), bladder cannulation for urine collections, and a jugular vein cannulation for reagent 
infusions (1mL FITC-inulin/100g animal body weight in isotonic saline for glomerular 
filtration rate (GFR) determination).  A cannula-sheathed 19g needle for instillation of Pi 
or saline solutions was placed into the duodenum (2-3cm from the stomach pylorus) 
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and secured with a ligature (in situ intestinal open loop technique).  Once surgery was 
completed, a bolus of 0.05% fluorescein isothiocyanate (FITC) tagged inulin, diluted in 
isotonic saline, was given as a primer via the jugular cannula and replaced the isotonic 
saline for infusion.  The animal was then maintained for 40 minutes for FITC-inulin 
equilibration and recovery from surgery (Figure 4.1). 
 
  
Figure 4.1.  Schematic of renal clearance surgery procedures and timeline 
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After the equilibration period, rats underwent the following protocol:  four consecutive 
collections of urine were made, each of 15 min. A small sample (500uL) of arterial blood 
was drawn at the start and then after each urine collection period for Pi and FITC-inulin 
measurements.   
 
After the first control (CTRL) urine collection, 1mL of phosphate solution containing 
either 10mM or 1.3M diluted in HEPES buffer (16mM Na-Hepes, 140mM NaCl, 3.5mM 
KCl, 10mM/1.3M KH2PO4, pH 5) and matching saline controls (154mM and 1.35M 
saline respectively) was instilled into the duodenum.  Osmolarity of buffers was 
assessed using a freezing point depression micro-osmometer (Model 3M, Advanced 
Instruments Inc, Massachusetts, US).  All instilled solutions were within the isotonic 
range (290-310 mOsm/L), except the 1.3M Pi and 1.35M saline (chosen to match the 
osmolarity of Pi solution), which presented an extremely high osmolarity.  The duodenal 
needle was then removed after instillation, and the intestine was tied off to prevent 
backflow of Pi buffer into the stomach.  After the last blood collection, the rat was killed 
by cardiac exsanguination and the kidneys and sections of intestinal mucosa were 
collected for brush border membrane vesicle preparation (Figure 4.1).  Both kidneys 
were decapsulated, excised and transferred to a beaker containing ice cold isotonic 
saline. The cortex of both kidneys containing the proximal tubules were removed by 
slicing off the outer layer with a scalpel on an ice-cold glass plate and snap frozen for 
subsequent brush border membrane vesicle preparation   
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4.2.3.  GFR and Pi measurements/calculations 
Blood was collected in tubes containing anticoagulant (EDTA) and kept on ice until 
processing after surgeries.  After the last blood collection, all tubes were centrifuged at 
6000rpm for 15 min at 4oC and the plasma was separated and frozen for future use in 
Pi and FITC assays.  Urine was immediately frozen for FITC assays.   
 
Plasma and urine were treated with 10% trichloroacetic acid (TCA) prior to Pi assays to 
remove bound protein that may affect Pi concentration.  Pi assays were performed 
according to the manufacturer’s instructions (Quantichrome DIPI-500, USA).  FITC-
inulin assays were performed in a 96-well plate and measured using a plate reader with 
a filter for 480nm.  FITC readings from blood collected at the beginning and end of the 
15 min urine collection period were averaged to represent FITC concentrations during 
the whole urine collection period.   
 
GFR was then calculated using the following equation:   
[FITC value for urine x flow rate (uL/min)] / average FITC reading from first and last 
plasma collection for the specific time period.  Absolute Pi values were obtained using 
this equation: 
Urine Pi concentration x urine flow rate  
 
Fractional excretion of Pi (FEPi, %) was calculated using the following equation:  
[([Pi] urine / [Pi] plasma) x (FITC plasma / FITC urine)] x 100 
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4.2.4.  Plasma PTH measurements 
PTH in plasma taken from the last blood collection (45 min after Pi/saline bolus) was 
measured using an enzyme-linked immunosorbent assay (ELISA) targeting rat bioactive 
PTH (Immunotopics, USA).  The ELISA was performed according to manufacturer’s 
protocol. 
 
4.2.5.  Kidney brush border membrane vesicle preparation 
Cortex from both kidneys, collected in the manner mentioned above, was suspended in 
30mL resuspension buffer 1 (300mM mannitol, 5mM EGTA, 12mM Tris-HCl, protease 
inhibitors, pH 7.4) and homogenised using an Ultra Turrax homogenizer for 2 min.  The 
homogenizer was then rinsed with 42mL cold dH2O and collected with the homogenate.  
This solution was then stirred on ice with the addition of 720 μL 1.2M MgCl2 (final 
concentration of 12mM MgCl2) for 15 min and then centrifuged at 4500rpm for 15 min at 
4oC.  Supernatant was obtained after centrifugation and further centrifuged at 
16000rpm, for 30 min to obtain a BBM containing pellet.  The pellet was resuspended in 
20mL of resuspension buffer 2 (150mM mannitol, 2.5mM EGTA, 6mM Tris-HCL, pH 
7.4) and hand homogenized using a Teflon hand homogeniser.  The homogenate was 
gently stirred on ice and a further addition of 200uL of 1.2M MgCl2 (final concentration 
of 12mM MgCl2) for 15 min and spun at low and high rpm as previously described.  The 
resulting pellet was resuspended with 20mL resuspension buffer 3 (300mM mannitol, 
12mM Tris-HCl, 2.5mM EGTA, pH 7.4) and hand homogenized in the same manner 
was above.  The homogenate was spun one final time at 16000 rpm for 30 min and the 
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resulting pellet was resuspended with 1mL of resuspension buffer 3 using a 21 gauge 
needle and syringe.  All steps were performed at 4oC. 
 
An alkaline phosphatase assay was utilized to determine enzymatic activity of the initial 
BBMV homogenate and the final protein concentration was obtained using a Bradford 
assay.  Taken together, these assays allowed overall purity of the BBM preparation to 
be determined [249, 250]. 
 
4.2.6.  Western blotting 
BBMVs (40 µg protein) were combined with 2x Laemmli Buffer (Bio-Rad) at a 1:1 ratio 
and further denatured at 90oC for 2 min.  Samples and a molecular weight marker (Bio-
Rad) were then run on a 10% SDS-PAGE gel and transferred onto a PVDF membrane 
using a semi-dry transfer system (Bio-Rad) for 1.5 hours at 120mA for 2 gels and 75mA 
for 1.5 hours for 1 gel.   The membranes were then blocked with 5% powdered milk 
diluted in 1x PBS and 0.1% Tween (PBST) for 45 min and incubated with a primary 
antibody overnight on a shaker 4oC.  Blots were washed 3 x 10 min with PBST and 
incubated with a horseradish peroxidase conjugated secondary antibody for 1 hour at 
room temperature on a shaker.   Membranes were washed again as described 
previously and proteins were detected using a homemade electrochemiluminscence 
reagent  (1.25mM 3-aminophthalic acid hydrazide aka luminol, 0.2mM  p-coumeric acid, 
500mM tris-HCl, 100mM NaCl, 21.5mM H2O2) .  Antibodies used:  primary:  rabbit anti 
NaPi-IIa, rabbit anti NaPi-IIc, (generous gifts from Biber J, Zurich Switzerland), loading 
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control ß-actin (Abcam); secondary – HRP conjugated donkey anti rabbit/mouse 
(Sigma).   
 
4.2.6.1.  Protein quantification and statistical analysis 
Protein bands were detected and quantified using densitometry using the Fluor-S 
MultiImager system (BioRad, Hertfordshire, UK).  Values are expressed in arbitrary 
units (a.u.) as a ratio of primary antibody protein intensity to ß-actin.  Data is presented 
as mean ± SEM and statistical significance is shown after analysis with a Student’s 
paired t-test with * denoting a P value of < 0.05 and ** denoting a P value of < 0.01.  P 
values were obtained comparing protein expression relative to the saline control. 
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4.3.  Results 
 
4.3.1.  Renal function and blood pressure of anesthatized rats maintained on a 
regular diet or low Pi diet over the course of the surgical procedure 
No significant changes in GFR and MAP were seen during surgeries for all groups of 
animals.  There was a trend in decrease of MAP as surgeries progressed - this is well-
documented effect of anesthesia [251] (Figures 4.2a and 4.2b).  There was one time 
point (45 min post-bolus) in which animals receiving a 1.35M saline load into the 
duodenum load showed a significant decrease in MAP compared to the control period 
(P = 0.016). 
 
 
  
 
Figure 4.2a. GFR and MAP data from clearance surgeries (regular diet) 
GFR values and MAP for clearance surgeries on animals maintained on a regular diet.  n = 4 (154mM saline), 5 (10mM Pi), 5 (1.35M saline), 7 (1.3M Pi).  
Data is presented as mean ± SEM, * denotes P < 0.05.     
* 
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Figure 4.2b. GFR and MAP data from clearance surgeries (low Pi diet) 
GFR values and MAP for clearance surgeries on animals maintained on a low Pi diet.  n = 5 for all parameters.  Data is presented as mean ± SEM.   
C
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4.3.2.  Effect of a 10mM Pi duodenal instillation on plasma Pi levels and urinary Pi 
excretion (regular diet) 
A 10mM Pi concentration was used to represent a physiological, post-prandial Pi 
concentration in the intestinal lumen.  No significant changes were seen in plasma levels, 
FEPi, or absolute urinary Pi excretion following a 10mM Pi duodenal challenge (Figure 
4.3a). 
 
4.3.3.  Effect of a 1.3M Pi duodenal instillation on plasma Pi levels, and urinary Pi 
excretion (regular diet) 
A 1.3M Pi concentration was used to directly replicate experiments conducted by Berndt et 
al (2007) [139, 140].  A significant increase in plasma Pi concentration was seen following 
Pi instillation into the duodenum (P values to control period:  15 min = 0.0018, 30 min = 1.8 
x 10-5, 45 min = 0.00039).  There was a significant increase in absolute urinary Pi excretion 
45 min post 1.3M Pi instillation into the duodenum. (P = 0.0435) and a trend in increase of 
FEPi in this group.  A similar trend in increase in FEPi and absolute urinary excretion of Pi 
was seen in animals that received a 1.35M saline bolus, however changes were not 
significant.  Data for absolutely excretion of Pi for 1.3M Pi and 1.35M saline duodenal 
instillation were expressed on separate graphs due to large differences in Pi excretion 
values (Figure 4.3b).   
 
 
  
 
Figure 4.3a.  Plasma Pi concentration and urinary Pi excretion data for animals that received a 10mM Pi duodenal instillation, maintained on a 
regular diet 
 n =  4 (154mM saline), 5 (10mM Pi).  Data is presented as mean ± SEM.   
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Figure 4.3b. Plasma Pi concentration and urinary Pi excretion data for animals that received a 1.3M Pi duodenal instillation and were 
maintained on a regular diet.   
n = 5 (1.35M saline), 7 (1.3M Pi).  Data is presented as mean ± SEM, * denotes P < 0.05.     
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4.3.4.  Effect of 10mM and 1.3M Pi instillation in the duodenum on expression of 
NaPi-IIa and NaPi-IIc protein at the renal BBM (regular diet)  
Western blots were performed utilizing kidney BBMVs prepared from corresponding 
animals post-mortem.  No changes was seen in renal protein expression of NaPi-IIa or 
NaPi-IIc following duodenal Pi instillation (Figure 4.4a and 4.4b) 
 
 
 
Figure 4.4a. NaPi-IIa and NaPi-IIc expression following a 10mM Pi duodenal instillation in animals 
maintained on a regular diet 
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Figure 4.4b. NaPi-IIa and NaPi-IIc expression following a 1.3M Pi duodenal instillation in animals 
maintained on a regular diet 
 
 
 
4.3.5.  Effect of 10mM Pi instillation in the duodenum on plasma Pi levels and urinary 
Pi excretion (low Pi diet) 
No significant changes were seen in plasma Pi levels, FEPi, or absolute urinary Pi 
excretion following a 10mM Pi duodenal challenge in animals maintained on a chronic low 
Pi diet  (Figure 4.5a). 
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4.3.6.  Effect of 1.3M Pi instillation in the duodenum on plasma Pi levels and urinary 
Pi excretion (low Pi diet) 
No significant changes were seen in FEPi, or absolute urinary Pi excretion following a 1.3M 
Pi load into the duodenum in animals maintained on a low Pi diet.  At all time points 
following duodenal Pi instillation, there was a significant increase in plasma Pi 
concentration.  P values:  15min = 2.3 x 10-4, 30min = 7.9 x 10-6, 45min = 5.8 x 10-5) 
(Figure 4.5b). 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4.5a.  Pi concentration and urinary Pi excretion data for animals that received a 10mM Pi duodenal instillation, maintained on a chronic 
low Pi diet 
 n = 4 (154mM saline), 5 (10mM Pi).  Data is presented as mean ± SEM.   
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Figure 4.5b. Pi concentration and urinary Pi excretion data for animals that received a 1.3 M Pi duodenal instillation, maintained on a chronic 
low Pi diet 
n = 4 (154mM saline), 5 (10mM Pi).  Data is presented as mean ± SEM, ** denotes P < 0.01.      
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4.3.7.  Effect of 10mM and 1.3M Pi duodenal instillation on NaPi-IIa and NaPi-IIc 
protein expression at the renal BBM (low diet)  
No changes was seen in protein expression of NaPi-IIa or NaPi-IIc following duodenal 
Pi instillation in animals maintained on a low Pi diet (Figure 4.6a and 4.6b). 
 
 
 
Figure 4.6a.  NaPi-IIa and NaPi-IIc expression following a 10mM Pi duodenal instillation in 
animals maintained on a chronic low Pi diet 
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Figure 4.6b. NaPi-IIa and NaPi-IIc expression following a 1.3M Pi duodenal instillation in animals 
maintained on a chronic low Pi diet 
 
 
4.3.8.  Effect of duodenal Pi load on plasma PTH levels 
There was no significant difference in plasma PTH levels between animals receiving a 
saline or 10mM Pi duodenal bolus in animals maintained on regular or a low Pi diet.  
Animals which received a 1.3M Pi duodenal load, whether on both regular and low Pi 
diets, showed significant increases in levels of PTH.  The increase in plasma Pi and 
PTH concentrations may explain the phosphaturia that was observed in these animals 
(Figure 4.7). 
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Figure 4.7. Plasma PTH levels in animals 45 min after a Pi or saline bolus into the duodenum  
PTH assays were performed using the last plasma collection in renal clearance surgeries as described.  
“LOW” denotes animals maintained for 7 days on a low Pi diet prior to clearance surgeries.   
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4.4.  Discussion 
 
Our knowledge of Pi homeostasis remains vague with regards to the initial events that 
occur after the intake of food and the subsequent Pi transport processes that take place 
in the GI tract.  In 2007, Berndt and colleagues proposed a novel mechanism in which 
Pi was excreted rapidly (less than 20 min) following an acute duodenal Pi load. This 
striking phosphaturia was independent of all known regulators of Pi [139, 140].  
Furthermore, when duodenal mucosa from animals that received a 1.3M Pi duodenal 
load was homogenized and infused into the blood circulation of other rats, phosphaturia 
also occurred – suggesting the secretion of an uncharacterised factor from the mucosa 
of upper small intestine [139, 140].  It has been theorized that this factor may be a yet 
undiscovered phosphatonin (see section 1.3), or one that has not been implemented in 
this proposed gastro-renal signalling, such as MEPE.   
  
There has been an increasing interest in the role of phosphatonins in regulating 
extracellular Pi as they have the potential to act more acutely on NaPis than known Pi 
regulators.  The rapid phosphaturic response to an intestinal Pi load shown by Berndt et 
al (2007) [139, 140] seemed to point to an unknown phosphatonin-like factor that 
induced a rapid Pi excretion without affecting the levels of known Pi regulators.  
Crucially, the phosphaturia occurred without a change in plasma Pi concentration.  
Berndt et al utilized intricate in vivo surgical techniques and present experiments were 
conducted as similar as possible in order to examine urine and plasma Pi concentration 
and expression of NaPi-IIa and NaPi-IIc protein following an acute Pi load.  Both a Pi 
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solution of a physiological concentration (10mM) was used as well as the 1.3M Pi buffer 
utilized by Berndt et al [140].  
 
One of the main concerns that led to the decision to reproduce these experiments 
involved the subsequent correction of Pi concentration utilized by Berndt et al which 
stated that an extremely concentrated 1.3M Pi solution was instilled into the duodenum 
rather than the originally stated 1.3mM Pi concentration [139, 140]. With this 1000x 
more concentrated solution used in their experiments, other factors such as the effects 
of increased osmolarity of instillate and damage to the apical membrane of the small 
intestine come into question and may potentially render previous results 
unphysiological.  Indeed, an observation noted during the present experiments was that 
intestinal morphology seemed markedly disturbed with an increase in mucous content in 
both 1.35M saline and 1.3M Pi compared to experiments utilizing isotonic solutions 
(Figure 4.8).  This phenotype was very drastic and immediately noticeable upon 
opening of the peritoneal cavity.  An increase in the production of mucous is usually 
viewed as a protective mechanism to prevent damage to epithelium [252] and the 
manner in which this affects Pi transport is unknown.   
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Figure 4.8.  Rat GI tract following duodenal instillation of 1.3M Pi (left)   
An increase in mucous production is clearly visible as compared to a segment of small intestine instilled 
with isotonic saline (right - image from [253]) 
 
 
According to the results from this study, there was only one time point in which a 
significant increase in urinary Pi excretion was seen and this was at 45 min after 
duodenal instillation of 1.3M Pi in animals maintained on a normal diet.  The fact that 
this increase in excretion was coupled with an increase in plasma Pi concentration 
leads to the conclusion that other factors are driving this phosphaturia such as the 
correlated increase in PTH.  The increase in urinary excretion also takes place at a later 
time point following duodenal Pi instillation than the phosphaturia observed by Berndt et 
al (phosphaturia occurred within 20 min) [139].  The variability of urinary Pi excretion in 
animals on a regular diet was also much greater than the group primed on a chronic low 
Pi diet - whether this has to do with the variability of existing intestinal luminal Pi 
concentrations immediately prior to surgery is unknown.  Present data represented 
surgeries performed around the same time each day, thus future experiments may 
address this issue by fasting animals briefly (4-5 hours) to normalize intestinal food 
content.   
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One of the responses to a high plasma Pi concentration is a rapid increase in plasma 
PTH levels (refer to section 1.8), which is shown in the present data.  There does not 
seem to be a significant change in plasma PTH in rats which received a physiological 
concentration of duodenal Pi (10mM) maintained on both low Pi and regular diets.  
However, 45 min after duodenal instillation of a 1.3M Pi solution, there is a marked 
increase in serum PTH in animals in both diet groups (Figure 4.7).  This increase in 
PTH may be the cause of the few cases of phosphaturia observed in regular diet-fed 
animals at 45 min following Pi bolus.  Moreover, this result is in direct contrast with the 
data from Berndt et al [139], which showed no increases in plasma Pi or PTH.  
Occurrence of phosphaturia in animals receiving a 1.3M Pi duodenal load can therefore 
be attributed to these changes in plasma Pi.  The animal group receiving a 1.35M saline 
duodenal load showed no significant increases in plasma PTH, thus the significant 
increase in urinary Pi excretion seen in this group was not a result of PTH.  The 
instance of significant increase in urinary Pi excretion 30 min following duodenal load of 
concentrated saline may thus be attributed to damage to intestinal structure and 
function.      
 
Interestingly, baseline FEPi of all animals used in present experiments was very low, 
with values all under 0.15%; the range of published FEPi values in Sprague Dawley rats 
vary from 2 - 28% [139, 254, 255].  The low FEPi could be directly attributed to 
observed low urinary Pi excretion; urinary Pi concentrations were confirmed by utilizing 
more than one established Pi assay (Quantichrome DIPI-500 and [256]).  The low FEPi 
values was the reason behind expressing Pi excretion data as an absolute urinary Pi 
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excretion value concurrently, as this method focused on absolute amounts of Pi rather 
than a percentage of Pi excreted.  Previous publications which have studied Pi handling 
in rats have also used absolute urinary Pi excretion to communicate their data [90, 91].  
Whether this low FEPi value is a trait of all Sprague Dawley rats from Charles River 
should be investigated as this may not represent physiological renal Pi handling.  It is 
important to note that plasma Pi levels of all animals used in the present study were 
within normal range, thus Pi homeostasis was not dysregulated.       
     
Utilizing BBM prepared from kidneys of Pi infused rats, it was apparent that a duodenal 
Pi load and the potential phosphaturic factor proposed by Berndt et al does not 
downregulate the expression of NaPi-IIa or NaPi-IIc at the apical membrane of the 
kidney.  The aforementioned variability of Pi excretion, in particular a few animals which 
were given a 1.3M Pi duodenal load and exhibited phosphaturia, do in fact correspond 
to a lower expression of NaPi-IIc (Figure 4.4b).  As mentioned in section 1.2.1.5, NaPi-
IIc does not play a large role in kidney handling of Pi; however, in response to a very 
high Pi load the mechanisms of Pi regulation may be altered.   
 
A recent study re-evaluating the established gastro-renal natiuretic signalling axis of 
guanylin, revealed that crosstalk between these two major organs may involve complex 
tangential pathways, other organs, and humoral factors [257].  Similarly, in the context 
of Pi regulation, it appears that the intestine and kidney interplay to maintain Pi 
homeostasis by mechanisms which are still unknown. Studies in man show that a Pi 
load presented to the jejunum increases related Pi regulatory factors such as PTH 
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without affecting other factors thought to be upstream of this sensing pathway (i.e. 
calcium levels) [258].  Other studies in CKD patients have shown that in contrast to the 
well documented association between FGF-23 and dietary Pi intake [142], acute non-
dietary modulation of serum Pi levels (e.g. IV) within the normal range does not induce 
changes in FGF-23 [259].  Therefore, it appears that intestinal Pi load and/or sensing 
may have the capability of regulating FGF-23 and PTH, which in turn would directly 
affect Pi reabsorption by the kidney.  
 
Patients with CKD are encouraged to reduce their dietary Pi load and there have been 
many subsequent reports of the impact, or lack thereof, of dietary intervention.  In rats, 
a decrease in dietary Pi coupled with Pi binders significantly reduced aortic calcification 
and kidney damage [164].  On the contrary, other comprehensive patient studies 
provide evidence that reduction of dietary Pi load does not reduce the probably of 
developing cardiovascular conditions and has no effect on mortality and the future 
development of renal damage [260].  What is known is that dietary Pi restriction and Pi 
binders both have poor patient compliance and more effective methods of Pi control are 
needed to manage hyperphosphatemia in CKD.   
 
4.4.1.  Summary and conclusions 
The present study investigated kidney Pi clearance in rats and showed that there is no 
increase in urinary Pi excretion up to 45 min following duodenal instillation of a 10mM or 
1.3M Pi solution.  Duodenal instillation of these Pi concentrations also did not 
significantly affect the overall expression of NaPi-IIa or NaPi-IIc proteins at the renal 
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BBM, however, a correlation was seen between reduced expression of these renal Pi 
transporters and phosphaturia presented in a few, specific animals given a 
supraphysiological (1.3M) Pi duodenal bolus.  These decreases in NaPi protein 
expression could be, in part, due to increases in plasma Pi and PTH concentrations 
seen in animals which received a 1.3M duodenal Pi load.   
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5.0.  Pi uptake by the liver 
 
5.1.  Introduction 
 
Pi signalling between organs is potentially important for supplementing the classical 
hormonal responses in the maintenance of Pi homeostasis.  Although the data 
presented in Chapter 4 suggests does not support the hypothesis of acute regulation of 
Pi between the intestine and the kidney, other organs may be involved in overall Pi 
balance.  The notion to investigate the role of the liver role in Pi handling was prompted 
by observations of low serum Pi following hepatectomy and in patients with liver 
diseases.  The initial reasoning for the occurrence of hypophosphatemia immediately 
following hepatectomy was the fact that the regenerating liver would require extra 
metabolic needs and, subsequently, more Pi from circulating blood [149].  However, the 
magnitude of the observed hypophosphatemia could not be accounted for solely by the 
demands of extra Pi being utilized for liver regeneration, thus other potential 
mechanisms were investigated to explain this clinical observation.  Nafidi et al as well 
as Salem et al revealed an early post-operative increase in fractional excretion of Pi 
post-hepatectomy, which was independent of plasma pH changes, and levels of  
FGF23, FGF7, sFRP-4 and PTH (after day one) [150, 151, 261].  The mechanisms 
behind this phosphaturic response have still not been uncovered. 
 
Certain liver processes are closely related to body Pi handling and regulation. The liver 
produces cathepsin B, a protease that cleaves a more recently characterized 
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phosphatonin MEPE into ASARM, another biologically-active phosphaturic factor; the 
basis for liver secretion of this enzyme and the method of its regulation are currently 
unknown [152].  Vitamin D, a main factor in Pi regulation, also has strong ties to the liver 
- one of the first steps of conversion of 7-dehydrocholesterol (cholecalciferol) into the 
active form of vitamin D occurs in the liver through the production of cholecalciferal 25-
hydroxlyase in its microsomes [146].    
 
In instances of CKD, parallels are also seen between alterations in receptor expression 
that happen within the liver and the kidney.  It has been shown that the PTH receptor in 
the liver is downregulated in a similar fashion to the renal PTH receptor amongst a 
surgically-induced CKD rat cohort [153], the function of which is again, still unknown.  
Interestingly, the calcium-sensing receptor (CaSR) has been shown to be expressed in 
hepatocytes and, when activated by excess levels of calcium, stimulates bile flow [262].  
This mechanism was thought to protect the liver against calcium accumulation that 
could potentially damage hepatocytes.  CaSR is vital in the PTH pathway of Pi 
regulation, in which activated CaSR prompts release of PTH and a subsequent increase 
in excreted Pi and a decrease in Pi absorption across small intestine (refer to section 
1.4.2.2.).  These findings further the notion that the liver may be a key player in Pi 
regulation and may be an intermediary in the previously proposed gastro-renal axis of Pi 
homeostasis. 
 
Another occurrence which points to the liver as a possible organ involved in Pi signalling 
and regulation involves the expression of type II and III sodium phosphate 
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cotransporters (NaPi-IIb and PiT1 and PiT2) in hepatocytes and cholangiocytes of the 
rat liver.  Experiments utilizing brush border vesicles prepared from these cells revealed 
that the sodium-dependent transport mechanisms and transport kinetics show 
similarities to transporters expressed in the kidney and small intestine.  The possible 
roles of these transporters in the liver were speculated to involve regulating biliary Pi 
concentration, as hepatocytes and cholangiocytes release ATP into bile which degrades 
to adenosine and Pi [13].   
 
A recent finding concerning liver x receptor (LXR) brings another receptor into the 
proposed function of the liver in the context of Pi handing.  Activation of the ubiquitously 
expressed LXR is known to modulate cholesterol trafficking out of various cell types in 
different tissue   Studies now show that agonists of the β isoform of LXR, which is 
expressed in greatest abundance in the liver, trigger a decrease in NaPiIIa and NaPiIIc 
expression in the kidney and subsequently, Pi transport in both the intestine and the 
kidney [263].  Again, the mechanistic significance of this regulation, and the role of LXR 
in the greater scheme of Pi homeostasis, is still unclear.   
 
Investigating the liver as a potential player in Pi regulation, in conjunction with the 
intestine and kidney, seemed to be a natural progression due to the location of the liver 
in the body and its function as an important metabolic organ.  The liver also receives 
70% of its venous blood supply from the portal vein, which consists of nutrient rich blood 
from the small intestine and pancreas [145].  Following this, the liver also metabolizes a 
substantial variety of compounds that are brought to it by the portal and systemic 
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circulations (refer to section 1.7), however, the direct interplay between the liver and Pi 
balance has not been previously investigated in vivo.   
 
5.1.1.  Aims of this study 
1.  To characterize Pi transport in the liver as compared with the established Pi 
transport mechanisms of the intestine; these studies will utilize 4 different 
concentrations of Pi in the buffer perfusing the small intestine (1, 5, 10, and 15mM) to 
represent a range of physiological luminal Pi concentrations. 
 
2.  To investigate the sodium dependency of Pi transport in the liver by utilizing 
intestinal luminal buffer with and without sodium.  Sodium-free buffers contained choline 
chloride (ChCl) as a substitute for sodium chloride (NaCl).   
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5.2.  Materials and Methods 
 
5.2.1.  Animal model 
Male Sprague Dawley (SD) rats between 250g-300g were obtained from Charles River 
laboratories (UK) and used in accordance with the Animals (Scientific Procedures) Act 
1986.  Rats were allowed ad libitum access to standard rodent chow containing 0.52% 
phosphate (Diet RM1, SDS Ltd, Witham, Essex UK) and water. 
 
5.2.2.  Liver Pi uptake, following in situ perfusion of the small intestine using the 
closed loop technique 
Anesthetic administration and femoral artery cannulation was performed as described in 
Chapter 2.2.3 to acquire blood samples at 10, 20, and 30 min following intestinal Pi 
instillation for Pi concentration analysis.  Plasma was obtained after centrifuging blood 
samples at 6000rpm for 10 minute at 4oC.   
 
Intestinal loop preparation was performed as mentioned in Chapter 2.2.3.  500L of 32P 
radio-labelled (0.37Mbq) Pi solution was added to buffer containing 16mM Na-HEPES, 
140mM NaCl, 3.5mM KCl, 1/5/10/15mM KH2PO4, (pH 7.4).  For experiments involving 
sodium-free buffer, NaCl was replaced with ChCl with all other concentrations of solutes 
remaining the same.  The HEPES buffer which was instilled into the jejunum was first 
assessed for its osmolarity using freezing point depression osmometry (micro-
osmometer; Model 3M, Advanced Instruments Inc, Massachusetts, US).  All solutions 
used for in vivo Pi uptake studies were within isotonic range (290-310 mOsm/L).   
Chapter 5 
 
 
158 
 
5.2.3.  Liver removal 
After 30 minutes, the last blood collection was performed and the animal was killed via 
cardiac exsanguination.  The whole liver was removed lobe by lobe, weighed, and 
approximately 100g was dissolved in Solvable (Perkin Elmer, MA, USA) protease 
solution overnight. 
 
5.2.4.  Exsanguination 
Experiments involving exsanguinations were performed immediately after blood 
collection at the last time point of 30 min.  An incision was made in the right atrium of 
the heart and 200mL of an ice-cold heparin/saline solution (1000iu/100mL saline) was 
manually infused via the femoral artery using a 50mL syringe to thoroughly flush out the 
blood from systemic organs. 
 
5.2.5.  Statistical analysis of radioactive counts 
Plasma was obtained after spinning down blood samples at 6000rpm for 10 min at 4oC 
and dissolved tissue was obtained via the method mentioned in the above section.  32P 
counts were measured using a Perkin-Elmer tri-carb 2900tr scintillation counter using 
4mL of Ultima Gold (Perkin Elmer) scintillant combined with 50uL plasma or 100uL 
dissolved liver tissue in triplicates.  The average was taken and converted to absolute Pi 
quantity in nmole units using values obtained by initial counts of undiluted 32P instillate 
solution.  Data is presented as means ± SEM and shows plasma Pi values at 30 min.   
A student’s paired t-test or an ANOVA, as appropriate, was used and group differences 
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were stated as statistically significant if P < 0.05; n represents the sample size of each 
experiment.   
 
5.2.6.  Calculations of Pi transport 
Calculations of Pi transport were performed by taking the 32P counts as mentioned in 
the section above and converting this to nmole Pi quantity and normalizing this value to 
1g of jejunal tissue per 1mL plasma collected.  
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5.3.  Results 
 
5.3.1.  Proof of principle - intestinal Pi transport as measured by appearance of 
32P in systemic blood 
For closed-loop surgeries looking at Pi transport in the liver, it was important to check 
that the animal was physiologically stable whilst anesthetized; this was determined by 
observing if there was constant Pi transport from the jejunum to systemic blood over 
time.  Blood was taken at 10, 20, and 30 min via the femoral artery and was counted for 
32P.  Significant increases were seen in Pi transport at 30 min between all 
concentrations of Pi instilled into the jejunum (Figure 5.1a) as well a steady amount of 
Pi transport over time during all experiments (Figure 5.1b).  P values Pi transport in the 
jejenum:  1 vs 5mM Pi = 2.80 x 10-5; 5 vs 10mM Pi = 1.65 x 10-4; 10 vs 15mM Pi = 
0.010.  n values for systemic blood:  1mM = 5; 5mM = 6; 10mM = 6; 15mM = 6. 
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Figure 5.1a.  Pi transferred by the jejunum as measured by appearance of Pi in plasma, a 
comparison between four Pi concentrations instilled into the jejunum  
1, 5, 10, and 15mM Pi diluted in HEPES buffer was used as the uptake solution.  Results represent Pi 
contained in plasma 30 min post-jejunal Pi load.  Significant changes are seen between each increase 
in Pi buffer concentration.  Data is presented as mean ± SEM with n=5-7.  
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Figure 5.1b.  Pi transferred by the jejunum as measured by appearance of Pi in plasma over time 
Three samples of plasma were collected during the course of the experiment, at 10, 20, and 30 min 
post-jejunal Pi load.  There is a steady and maintained level of Pi in the blood over time with no 
significant decreases by 30 min, which validates the animal model used.  
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5.3.2.  Pi transferred into the liver following jejunal Pi load in situ  
Pi uptake by the liver was investigated using an in situ jejunal closed-loop technique 
utilizing 500 L of 1, 5, 10, and 15mM radiolabelled Pi solution containing sodium.  
Results showed a steady and significant increase of Pi uptake at increasing Pi 
concentration and an insignificant change between 10mM and the highest concentration 
of 15mM, perhaps signifying that the organ has reached Pi saturation (Figure 5.3). P 
values liver:  1 vs 5mM = 7.94 x 10-6; 5 vs 10mM = 0.0181; 10 vs 15mM = 0.549.  n 
values for liver:  1mM = 5; 5mM = 4; 10mM = 5; 15mM = 7.   
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Figure 5.2. Pi transferred into the liver, a comparison between four Pi concentrations instilled 
into the jejunum  
Significant increases in the amount of Pi taken up by the liver were seen between 1 and 5mM as well as 
between 5 and 10mM.  There is a noticeable plateau between 10 and 15mM Pi which may signify 
saturation of the transport process.  Data is presented as mean ± SEM with n=4-7.   
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5.3.3.  Sodium-dependent Pi uptake into the liver following Pi load into the 
jejunum in situ 
Sodium-dependent uptake by the liver was investigated by instilling radiolabelled Pi 
solution with or without sodium directly into the jejunum utilizing the in situ closed-loop 
technique described previously in Chapter 2.2.3.  Results indicate significant sodium 
dependent Pi transport by the jejunum (as measured by Pi appearance in blood) at all 
concentrations of Pi instilled into the jejunum (Figure 5.4a).  However, sodium 
dependency was not seen in the liver apart from at 15mM Pi jejunal instillation (Figure 
5.4b).  Results compared animals that received Pi into the jejunum in the presence of 
sodium (Na) with animals that received Pi into the jejunum in a choline chloride-based 
buffer (ChCl).  P values were:  1mM = 0.427, 5mM = 0.0175, 10mM = 0.103, 15mM = 
0.028).  n values for animals receiving Pi in presence of Na were same as in figure 5.1.  
n values for Pi uptake in the presence of ChCl:  1mM = 5, 5mM = 6, 10mM = 6, 15mM = 
7.  P values of Pi uptake by the liver in presence of Na vs ChCl animals at 30min were:  
1mM – 0.658, 5mM – 0.838, 10mM – 0.759, 15mM – 0.0156).  n values for Pi uptake by 
the liver in the presence of Na were the same as in figure 5.2.  n values for Pi uptake by 
the liver in the presence of ChCl:  1mM = 5, 5mM = 4, 10mM = 5, 15mM = 7.   
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Figure 5.3a. Sodium-dependent Pi transport by the jejunum following Pi load, as measured by 
appearance of Pi in plasma 
Shaded bars represent Pi uptake in the presence of sodium (Na) while checkered bars represent Pi 
uptake with a sodium-free buffer (ChCl).  Data is presented as mean ± SEM with n = 5-7.     
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Figure 5.3b. Sodium-dependent Pi uptake by the liver following a jejunal Pi load 
Shaded bars represent Pi uptake in the presence of sodium (Na) while checkered bars represent Pi 
uptake with a sodium-free buffer (ChCl).  Data is presented as mean ± SEM with n = 5-7. 
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5.3.4.  Pi transferred into the liver following exsanguinations 
Exsanguinations were performed to confirm that measurements of Pi uptake 
represented the Pi contained in liver hepatocytes and not the Pi contained in the blood 
present in the liver.  Results showed no significant differences in Pi amounts contained 
in liver obtained without exsanguinations and those with exsanguinations (Figure 5.5).  
n values for regular liver collection:  1mM = 5; 15mM = 7; exsanguinations:  1mM = 5; 
15mM = 5. 
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Figure 5.4.  Amount of Pi taken up by the liver in animals following exsanguination compared to 
standard liver extraction following sacrifice 
Liver taken from animals immediately after surgery are grouped as “normal”.  There are no significant 
differences in Pi amount contained in the liver between these two groups.   
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5.3.5.  Pi in hepatic portal vein blood vs. systemic blood 
Pi was measured in plasma collected from the hepatic portal vein (HPV) in animals 
instilled with 10mM Pi solution and compared with the Pi levels in systemic plasma to 
assess whether there were any significant differences between Pi concentrations in 
these two points of the circulatory system.  Animals instilled with Pi in NaCl or ChCl 
buffer were also compared to examine if there were different sodium-dependent 
mechanisms displayed at different locations of plasma collection.  Results showed that 
Pi contained in portal blood and systemic blood collected from the femoral artery was 
comparable with no significant differences (Figure 5.6).  P values: systemic vs HPV 
+Na = 0.915; systemic vs HPV ChCl = 0.457; n  values:  systemic plasma = 6; HPV = 4.  
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Figure 5.5.  Pi content of plasma collected from the hepatic portal vein (HPV) compared to blood 
collected from the femoral artery following 10mM Pi instillation into the jejunum 
Pi measured in systemic plasma is represented by a solid bar, and Pi in HPV plasma shown by a 
checkered bar.  No significant differences are seen between plasma Pi from systemic and HPV 
collection sites in both groups of animals (Pi instilled in presence of NaCl or ChCl).  Data is presented 
as mean ± SEM.   
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5.4.  Discussion 
 
The idea that the liver may potentially be involved in Pi homeostasis was speculated 
following observations of Pi imbalances seen after certain liver procedures.  This idea 
related back to  observations of acute hypophosphatemia in patients following 
hepatectomy [149].  This phenomenon was eventually attributed to increased 
phosphaturia which occurred independently of the major known mediators of Pi 
homeostasis (PTH and phosphatonins) [150].  The underlying mechanism and cause for 
hepatic-related phosphaturia remain unidentified.  
 
In 2004, both type II and III sodium phosphate transporters were found to be expressed 
in the liver and their roles in this organ revolved around regulating bile Pi concentrations 
[13]. The function of the liver in secreting phosphatonin-specific proteases such as 
cathespin B, also suggested that the liver may have a role in Pi homeostasis.  
Combined, this knowledge about the function of the liver made it an appealing organ to 
focus on in the present Pi transport experiments.  
 
The results from liver Pi uptake experiments utilizing the in situ intestinal closed-loop 
technique conclude that the liver accumulates more Pi when higher concentrations of Pi 
is instilled into the jejunum.  This pattern is equivalent to Pi transport mechanisms seen 
in the small intestine as measured in systemic plasma.  The trend for apparent 
saturation of Pi uptake when 15mM Pi is instilled into the jejunum is interesting, since it 
represents a Pi concentration saturation range for the liver.  The range of intestinal 
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luminal Pi concentration in man has been shown to be approximately 0.7-12mM 
depending on the timing and composition of food [119].  Previous work in our group has 
shown that intestinal luminal Pi concentration in Sprague Dawley rats ranged from 7-
11.5mM [200], thus 15mM may be just over this physiological spectrum.  Data from 
these experiments suggest that there is a Pi secretory function for the liver at 
supraphysiological Pi concentrations which may protect the rest of the body from 
excess Pi by secreting it back into the bile to be recirculated into the small intestine.  It 
would be interesting to see whether this seemingly saturable Pi uptake would maintain 
its pattern at Pi concentrations even higher than 15mM. However, higher concentrations 
of Pi were not used since these levels of Pi are not physiologically relevant.  
 
Sodium dependent Pi uptake of the liver was also investigated by substituting ChCl for 
NaCl in the Pi buffer instilled into the jejunum.  Results show a differing pattern in 
sodium dependency between the small intestine and the liver.  Sodium-dependent Pi 
transport was evident at all concentrations of Pi instilled into the jejunum.  In the liver, 
however, sodium dependency was only seen at 15mM Pi.  Again, at this concentration, 
which is on the cusp of being a high luminal Pi load, different mechanisms of Pi uptake 
seem to be triggered.  This may suggest that the sodium-phosphate cotransporters 
expressed in the liver may only be responsible for a small role in Pi transport at 
physiological levels and/or could be a part of a greater network of Pi handling that is still 
yet to be discovered.     
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The total amount of Pi taken up by the liver was similar to the amount transported by the 
jejunum, with less than 0.5% of Pi taken up from the starting buffer.  This may signify 
that under normal physiological conditions, the role of the liver may not weigh heavily on 
maintaining overall Pi homeostasis.  It is possible however, that when Pi regulation is 
dysregulated under the conditions of chronic kidney disease, the liver may play a more 
important part in Pi buffering.     
 
One observation taken from the results of HPV compared with systemic plasma Pi 
concentrations was the phenomenon of a seemingly lack of concentrated Pi being 
actively transported by the jejunum.  In theory, following an acute Pi load in the 
intestine, the excess Pi in the intestinal lumen would trigger Pi transport and the Pi 
amount in HPV plasma (plasma made up, in part, from the small intestine) would be 
greater than the amount in the circulation.  However, at 30 min, when these samples 
were taken, no significant changes were seen between HPV and systemic plasma.  One 
possible reason for this observation could be that at 30 min, Pi levels have normalized 
throughout the circulatory system and the initial predicted high levels of Pi concentration 
in the HPV would be at a level equal to Pi concentration in the rest of the circulatory 
system.  An experiment that could perhaps address this suggested explanation would 
be to cannulate the hepatic portal vein and take blood samples at earlier time points to 
see if there is an initial increase in Pi transport, proving the principle of active transport.  
Furthermore, experiments involving exsanguinations also confirmed that the Pi 
measured was contained in hepatic cells and not in the blood of the liver.  These 
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experiments were necessary to conclude that the liver cells themselves were taking up 
Pi. 
 
In addition to the experiments presented in this chapter, future studies should include 
the investigation of bile composition.  Bile is an intricate secretory product produced by 
the liver and serves two principal functions:  1) eliminate many endogenous and 
exogenous waste products from the body, such as bilirubin and cholesterol, and 2) 
promote the digestion and absorption of lipids from the intestine.  The composition of 
bile is modified significantly as a result of the absorptive and secretory properties of 
epithelial cells that line the intrahepatic and extrahepatic bile ducts.  Knowing that PiT-1 
and PiT-2 are expressed in bile duct cholangiocytes is a starting point in investigating 
the involvement of bile as a vehicle of Pi excretion.  Further studies could involve 
cannulating the bile duct and observing whether changes in bile Pi concentration occur 
following jejunal instillation of supraphysiological levels of Pi and whether inhibition of 
the process of Pi transport into bile leads to a dysregulation of body Pi homeostasis.  
Protein expression of PiT-1 and PiT-2 could also be investigated to reveal Pi uptake or 
secretion mechanisms along the bile duct.       
 
In 1980, a potential “portal factor” responsible for regulating calcium homeostasis was 
suggested [264] .  Using experiments similar to those mentioned in this chapter, the 
group measured plasma calcium levels in portacaval shunted Lewis rats following 
parathyroidectomy.  The results showed that there was correction of hypocalcaemia in 
shunted mice that was independent of PTH, and the data suggested a substance 
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originating in the portal region that bypassed modifications in the liver and was able to 
correct the hypocalcemia following parathyroidectomy [264].  The portal factor 
regulating whole body calcium balance could be similar to the unknown factor proposed 
for Pi regulation, since hepatectomy could alter the modification abilities of the liver. 
 
5.4.1.  Summary and conclusions 
The liver absorbs more Pi with increasing levels of Pi instilled into the jejunum (1, 5, 10, 
and 15mM) and the uptake process reaches a saturation point at 15mM since no 
significant increase is seen between the amount transported at 10mM.  The liver also 
transports Pi in a mostly sodium-independent manner in vivo up to supraphysiological 
concentrations (15mM) where saturation occurs.  The mechanisms involved in this 
physiological response, however, are unknown but the excess Pi may be released into 
the bile for secretion into the intestine.  In this way, the liver may serve as a Pi sensor 
and act as a protective mechanism and act in concert with the phosphaturic action of 
PTH to minimize increases in plasma Pi concentration. 
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6.0.  General discussion and future experiments 
 
6.1 Brief background to intestinal, renal, and hepatic Pi handling 
 
To date, there have been numerous studies focusing on the mechanisms of renal and 
intestinal Pi transport, while also elucidating the specific impact of sodium-dependent 
phosphate cotransporters (NaPis and PiTs) in these tissues on overall Pi homeostasis. 
It is slowly becoming evident that there is complex interplay between the small intestine 
and kidney and that the liver may also play a role in these signalling pathways.  The 
proposed cross-talk between the intestine, kidney, and liver needs to be characterized 
in order to offer more targeted treatments of diseases of Pi imbalance such as hypo- 
and hyperphosphatemia, specifically in the context of chronic kidney disease (CKD). 
 
It has been previously established that the kidney plays a major role in maintaining Pi 
homeostasis via the sodium phosphate cotransporter, NaPi-IIa, at the proximal tubules.  
The kidneys filter Pi in the blood and about 80% of this load is then reabsorbed mainly 
by NaPi-IIa at the proximal tubule (Figure 1.1).  However, in specific subgroups of 
patients with CKD and subsequent hyperphosphatemia, impairment of renal function 
rules out the kidney as a target to treat Pi overload.  Much focus has since been placed 
in investigating the mechanisms of intestinal Pi transport and its potential as a main 
option for therapeutic intervention.  Studies have attempted to tease out the overall 
involvement of intestinal NaPi-IIb in postprandial Pi absorption and ascertain the relative 
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importance of paracellular (passive) and transporter-mediated (active) transport to 
overall Pi transport [12, 131, 132].   
 
During the investigation of intestinal Pi transport, Berndt et al [139] discovered that 
introducing a high concentration of Pi into the upper small intestinal lumen produced a 
rapid increase in urinary Pi excretion, which was not due to known regulators of serum 
Pi levels such as PTH and FGF-23 [139].  It was concluded that a novel signalling factor 
originated from the duodenum, as mucosal extracts from Pi treated animals infused into 
other animals also elicited this phosphaturic response.  More recently, a group in Japan 
found a liver-derived factor that affected renal reabsoprtion of Pi in rat models of CKD 
as well as in proximal tubule cell lines [154].  These latest findings point to an intricate 
Pi regulatory system which may involve multiple organs and different pathways. 
 
A primary aim of the experiments reported in this thesis was to characterize intestinal Pi 
transport by directly comparing widely-used in vitro and in situ techniques in five 
different regions of the intestinal tract (duodenum, jejunum, ileum, proximal colon, and 
distal colon).  These experiments utilized the in vitro everted sleeve and the in situ 
intestinal closed-loop techniques and served to clarify discrepancies seen in published 
results regarding intestinal Pi transport.  Critical analysis of which specific technique 
would be more appropriate for investigating Pi transport in different regions of the 
intestine was also conducted based on how Pi uptake is measured using in vitro and in 
situ methods.     
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The next goal was to establish an ex vivo intestinal perfusion technique to investigate 
intestinal Pi transport.  Data obtained from this method offers advantages in 
understanding how Pi is transported directly across the intestinal epithelium since 
serosal fluid is collected and analyzed from perfused intestine.  The composition of this 
serosal fluid can be interpreted to directly represent the Pi passing through the intestine 
whereas previously discussed in vitro and in situ methods measure Pi taken up at the 
BBM and Pi appearance in blood circulation respectively.   The ex vivo technique has 
already been used to investigate the absorption of flavonoids and hydroxycinnamates, 
olive oil polyphenols, clinical drugs, and glucose [215-219].  Present studies 
investigated the sodium-dependent component of Pi transport utilizing this technique by 
perfusing the intestinal segment with a sodium-free perfusate.   
 
One of the main issues to address during this project was the hypothesized gastro-renal 
Pi signalling axis.  The objective was to directly replicate and further the renal clearance 
studies by Berndt et al [139, 140] using a physiological Pi concentration instilled into the 
duodenum (10mM).  The reported phosphaturia by Berndt et al followed a 1.3M Pi 
duodenal load [140] – this concentration of Pi was also utilized in the renal clearance 
experiments contained in Chapter 4.  Renal NaPi-IIa and NaPi-IIc protein levels were 
also quantified by preparing BBM vesicles from the kidneys of animals receiving a Pi or 
saline duodenal bolus and probing with antibodies against these transporters.  It has 
previously been shown that acute adaptations to an intestinal Pi load, in the form of 
altered expression of NaPi transporters, are more pronounced after priming animals on 
a chronic low Pi diet [62].  Thus another set of animals were also maintained on a low Pi 
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diet before clearance surgeries to prime renal NaPi-IIa and NaPi-IIc expression; the low 
Pi diet group would potentially exhibit quantifiable changes in protein expression 
following intestinal Pi load.     
 
Lastly, the role of the liver in overall Pi handing and homeostasis was investigated using 
the aforementioned in situ closed-loop technique with 32P labelled Pi buffer using four 
different Pi concentrations (1, 5, 10, and 15mM).  The liver was subsequently removed 
and 32P counts were measured; from this data, the total Pi transferred into the liver was 
calculated and compared with known Pi transport mechanisms of the jejunum.    
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6.2 Assessment of regional differences in intestinal Pi transport 
using in vitro and in situ techniques 
 
A large range of methods is relevant to the study of solute transport across the intestinal 
epithelium; however comprehensive comparisons between these techniques have not 
been previously conducted.  The experiments in Chapter 2 aimed to reveal the 
differences between Pi transport data obtained by two broadly used methods, the in 
vitro everted sleeve technique and the in situ intestinal closed-loop technique.  It is 
important to emphasize that the in vitro everted sleeve technique produces data that 
represents Pi uptake at the intestinal BBM and the in situ intestinal closed-loop 
technique measures transepithelial Pi transport by appearance of Pi in the blood.    
 
In these studies, three different concentrations of Pi (0.1, 1, and 10mM) were used to 
examine Pi transport in the intestine since postprandial intestinal luminal Pi 
concentrations are within this range [119].  Data showed that increasing the Pi 
concentration up to 10mM caused a corresponding rise in total Pi absorption in both in 
vitro and in situ data using both techniques.  The jejunum is also the area with the 
highest magnitude of Pi transport, which corresponds appropriately with previously 
published data of high levels of intestinal phosphate transporter NaPi-IIb mRNA and 
protein expression in this region of rat intestine [17, 62]. 
 
In terms of overall Pi transport ability, in situ data from the ileum show higher a 
magnitude of Pi transport than previously published data.  Although the ileum does not 
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transport as much Pi quantitatively as the proximal small intestine (duodenum and 
jejunum), it still exhibits substantial Pi transport compared to the colon.  In contrast, the 
ileum transports the least amount of Pi of all the intestinal regions in vitro.  These 
discrepancies may be related to known variations in intestinal content transport time.  
Chyme remains in the rat ileum for the longest period of time (~2-3 hours) [202], thus a 
2 min incubation time with 32P may not have accurately represented physiological Pi 
transport ability in this region.   
 
Using the in vitro everted sleeve technique, the distal colon unexpectedly transported 
near equivalent amounts of Pi as the small intestine, also with significant sodium 
dependency.  To date there have been numerous clinical observations of 
hyperphosphatemia following Pi-containing enemas, first described in 1977 [203], and 
current results may explain these clinical occurrences.  On the other hand, the in situ 
distal colon data shows that this mechanism of Pi transport is sodium-independent at all 
Pi concentrations used, thus following in situ manipulation, the distal colon epithelium 
may simply be more permeable to solutes.  In either instance, the amount of unbound 
Pi in the large intestine is thought to be negligible, hence the Pi transport data from both 
of these techniques may not actually occur under physiological circumstances.  
Although small amounts of Pi is available for binding at this point of the GI tract, there 
may be a mechanistic importance of Pi transport in the distal colon.  Short chain fatty 
acids, which are in abundance in the colon, displace Pi from anion exchanger sites in 
distal colon [204], thus making small quantities of Pi available for absorption.  
Furthermore, the effectiveness of current treatments of hyperphosphatemia with oral Pi 
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binders may be affected if displaced Pi becomes available at this part of the GI tract.  
Although it has been reported that mRNA of both NaPi-IIb and PiT1 [265] are present in 
the distal colon whether Pi transport in this region has any significance to overall Pi 
homeostasis is still yet to be investigated.  Interestingly, Capuano et al [265] detected 
mRNA of NaPi-IIb and PiT1 in the distal colon and both appeared to be regulated by a 
low Pi diet in a similar fashion to the known PiT1 expression in the small intestine [62].  
 
Discrepancies are seen in sodium-dependent Pi transport between data obtained from 
in vitro everted sleeve and in situ closed-loop techniques.  Apart from the jejunum and 
proximal colon, which exhibits sodium dependency and no sodium dependency 
respectively across all concentrations utilized, all other segments displayed varying 
results.  In vitro data showing sodium dependent Pi transport in the duodenum might 
have been due to the pH of solution, representing a greater amount of NaPi-IIb 
transport activity than PiT1 as NaPi-IIb activity is maximized at a neutral to basic pH 
[31].  PiT transporters are also not solely dependent on sodium to drive Pi transport as 
lithium has been shown to be able to substitute for sodium and transport Pi at a lower 
capacity [61].  Both NaPi-IIb and PiT1 proteins, however, are not highly expressed in 
the duodenum [17], thus data contained in Chapter 2 may point to an unidentified 
transporter.  Known variations in intraluminal pH along the intestinal tract might also 
explain the differences in data obtained from the two techniques in different regions of 
the intestine.  The proximal small intestine starts off relatively acidic (pH of 5.5-6) and 
increases to an almost neutral state in the distal ileum [205].  All of the solutions used in 
these experiments were adjusted to a physiological pH of 7.4, thus transporters which 
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may function at a higher capacity in an acidic pH environment may not have been 
operating (e.g. PiT1) [61].     
 
Data from in situ experiments show no sodium dependency of Pi transport in the 
duodenum.  This distinct contrast to data from in vitro studies which showed sodium-
dependency at all concentrations of Pi in the duodenum may be explained by regional 
differences in intestinal luminal transit times; ingested food remains in the duodenum for 
minutes compared to hours in the jejunum/ileum [202].  In this regard, the in vitro 
everted sleeve technique may be a representative model for duodenal Pi  transport, 
since Pi uptake was measured for a 2 min period in this intestinal segment.  
 
The in vitro everted intestinal tissue is constantly exposured to stirred Pi buffer ensuring 
a consistant Pi concentration close to the BBM, whilst the Pi buffer utilized in the in situ 
technique is relatively stagnant within the closed-loop.  The differences in Pi transport 
magnitude between the two techniques (higher amount of Pi transported utilizing the in 
vitro technique) may be explained by this difference in Pi measurement.  It is also 
important to recognize that the Pi exit pathway through the basolateral membrane is still 
unknown. 
 
Importantly, EM analysis on intestinal tissue segments used in both in vitro and in situ 
techniques show that the intestinal ultrastructure is not compromised and differences in 
Pi transport does not represent increased passive permeability across a damaged 
epithelium.  EM images revealed the tight junctions and intestinal villi to be intact 
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following manual handling using both methods and all segments of intestine utilized.  
Differences in magnitude of Pi transport and sodium dependency using both methods 
are thus attributed to factors other than structural explanations.   
 
6.3. Pi transport across the rat intestinal epithelium 
 
In Chapter 3, a novel application of the ex vivo intestinal perfusion technique to 
measure transport of Pi across the intestinal epithelium is demonstrated.  Here, data 
obtained from the serosal fluid of these experiments show for the first time that there is 
an increased Pi concentration directly absorbed across the intestinal epithelium 
compared to that in the perfusate.  These results confirm that active transport of Pi is 
taking place in the small intestine.    
 
Initial experiments using buffer containing 1.2mM Pi show an approximately 2-3x 
concentrated level of Pi in the serosal fluid.  Additional experiments were conducted 
using sodium-free perfusate to investigate sodium-dependent Pi transport.  A significant 
decrease in Pi transport was seen 20-40 min following the switch to sodium-free buffer 
as well as an increase in Pi transport following the switch back to a sodium-containing 
buffer (also between 20-40 min after the switch).  The lag-time in the transport response 
to switching between the two perfusates is speculated to represent the time taken for 
solute transport to reach equilibrium.  Thus the serosal fluid collected during the first 20 
min of exposure to sodium-free buffer may partially represent the Pi transported in the 
presence of sodium-containing buffer.   Additionally, the concentration of Pi measured 
Chapter 6 
 
 
181 
in the serosal fluid was confirmed to not be attributed to contamination of serosal fluid 
with liquid paraffin.  From these data, it can be concluded that sodium-driven 
accumulation of Pi is indeed a feature of transport across the small intestinal epithelium. 
 
In the present perfusion experiments, glucose transport across the intestine is 
inconsistent; when utilizing 10mM glucose since a significant reduction in glucose 
concentration was detected in serosal fluid compared to perfusate.  Studies by others 
have used glucose transport as a reflection of intestinal tissue viability [220],  however, 
it is evident that following the switch from sodium-free perfusate back to sodium-
containing perfusate, there is a trend towards an increase of glucose transport.  This 
pattern of glucose transport upon reintroduction of sodium-containing perfusate towards 
the end of the experiment, along with the continuous and sustained active Pi transport 
observed, indicates viability of the intestinal tissue. Previous studies show that intestinal 
tissue remains viable upwards of 120 min following removal from the blood supply [214, 
225] and perfusion experiments presented in this thesis were designed to fit within that 
time frame.   
 
There are changes in protein levels of claudin-1 and occludin, key constituents of tight 
junctions in the intestine, following induction of CKD in rats [138].  These alterations in 
the tight junctions of the intestinal epithelium mimic changes that occur following 
damage to the epithelium [137].  Disturbances in the architecture of tight junctions may, 
in turn, passively release more solutes into the bloodstream perhaps in an unregulated 
manner. Interestingly, mutations in genes encoding for claudin 16 produce phenotypes 
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of hypomagnesemia with hypecalciruria [236-238], features that may perhaps be related 
to the mechanisms of hyperphosphatemia seen in CKD.  Since tight junctions may 
regulate the still uncharacterized sodium-independent Pi transport pathway, these 
changes need to be investigated further to elucidate their relevance to intestinal Pi 
transport in the context of CKD.  Future experiments could involve utilizing the ex vivo 
perfusion method using intestinal tissue from CKD-induced rats and comparing results 
between control and CKD animals.   
 
The use of mannitol to examine paracellular intestinal transport of solutes could also be 
conducted utilizing this same technique.  However the charge and size of mannitol are 
markedly different to the Pi anion (PO42-) and thus the amount of paracellular transport 
occurring would only be a rough estimate of overall intestinal epithelial permeability.  
Although there are pitfalls, intestinal mannitol transport data can be used to correct for 
paracellular transport when observing Pi concentrations in serosal fluid.  The serosal 
fluid could also contain phosphaturic factors that have been implicated in the intestinal-
kidney signalling axis such as FGF-23 or MEPE.  In the present studies, very few 
samples of serosal fluid were of sufficient volume to conduct assays for components 
other than glucose and Pi. 
 
6.4. Gastro-renal Pi signalling axis 
 
In 2007, Berndt and colleagues reported a novel mechanism by which Pi was rapidly 
excreted (within a 20 min period) following an acute duodenal Pi load. This 
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phosphaturia was independent of most known regulators of Pi excretion such as PTH, 
FGF-23, sFRP-4, and elevated serum Pi in general [139, 140].  Furthermore, when a 
homogenate of duodenal mucosa from animals receiving a duodenal Pi load was 
infused into the blood of a separate group of rats, phosphaturia also occurred – 
suggesting that there is a uncharacterized factor located in the mucosa of the proximal 
small intestine.  It has been theorized that this Pi sensing element may be a yet 
undiscovered phosphatonin (see section 1.3), or one that has not been implicated in 
this proposed gastro-renal signalling, such as MEPE.   
  
The in vivo clearance surgeries described in Chapter 4 were conducted as similar as 
possible to those described by Berndt et al [139, 140] in order to examine urine and 
plasma Pi concentration and expression of NaPi-IIa and NaPi-IIc protein following an 
acute intestinal Pi load.  The experiments utilized both a physiological concentration of 
Pi (10mM) as well as the 1.3M Pi buffer utilized by Berndt et al [140].  According to the 
results from experiments contained in this thesis, there was only one time point in which 
a significant increase in urinary Pi excretion was seen and this was at 45 min after 
duodenal-instillation of 1.3M Pi in animals maintained on a normal diet.  The fact that 
the increased urinary Pi excretion was coupled with an increase in plasma Pi 
concentration reveals that other factors may be responsible for this phosphaturia, such 
as the correlated increase in blood levels of PTH.  The increase in urinary Pi excretion 
was also shown to occur at a later time point following duodenal Pi instillation than that 
observed by Berndt et al, who noted that phosphaturia occurred within 20 min [139, 
140].   
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In addition to replicating the experiments of Berndt et al, another group of animals were 
also fed a low Pi diet for 7 days prior to clearance measurement in order to increase the 
expression of renal sodium-phosphate transporters and make it more likely to observe 
changes in protein expression of NaPi-IIa and NaPi-IIc following an intestinal Pi load 
[62].  One of the main differences between data obtained from animals on a low Pi diet 
and animals on a normal diet was the variability of urinary Pi excretion.  Animals on a 
regular diet had a wider range of urinary Pi excretion than the animals fed a chronic low 
Pi diet - whether this has to do with the variability of existing intestinal food content and 
luminal Pi concentrations prior to surgeries in animals on normal diet is unknown.  
Future experiments could address this issue by fasting animals briefly (4-5 hours) to 
normalize the amount of intestinal food content.   
 
One of the responses to a high plasma Pi concentration is a rapid increase in plasma 
PTH levels (refer to section 1.8), which is also shown by the data in Chapter 4.  There 
was no significant change in plasma PTH levels of rats maintained on both low Pi and 
regular diets which received a physiological concentration of Pi (10mM) in the 
duodenum.  However, 45 min after duodenal instillation of a 1.3M Pi solution, there is a 
significant increase in serum PTH amongst animals in both diet groups.  This increase 
in PTH may be the cause of the few cases of phosphaturia observed in regular-diet fed 
animals at 45 min following a Pi bolus.  Moreover, this result is in direct contrast with the 
data of Berndt et al, which failed to detect elevations in plasma levels of plasma Pi or 
PTH.  The most obvious interpretation of data obtained from present experiments is that 
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phosphaturia in animals which received a 1.3M Pi intestinal load can be attributed to the 
resultant increase in plasma Pi and PTH concentration.   
     
Utilizing BBM prepared from kidneys of rats receiving a duodenal Pi or saline bolus, it is 
shown that a duodenal Pi load and the potential phosphaturic factor proposed by Berndt 
et al does not downregulate the expression of NaPi-IIa or NaPi-IIc at the renal BBM.  
The aforementioned variability of Pi excretion, in particular a few animals which 
received a 1.3M Pi duodenal load and exhibited phosphaturia, do in fact correlate with a 
lower expression of NaPi-IIc.  As discussed in section 1.2.1.5, NaPi-IIc does not play a 
dominant role in kidney handling of Pi; however in response to a very high Pi load the 
mechanisms of Pi regulation may be altered and NaPi-IIc may assume a more 
important role in renal Pi reabsorption.   
 
Berndt et al [139] corrected their published 1.3mM Pi buffer utilized in their experiments 
to 1.3M Pi solution [140].  With this 1000x more concentrated Pi solution, present work 
revealed morphological changes in intestinal ultrastructure.  Particularly noticeable was 
a marked increase in intestinal mucus production following both 1.35M saline and 1.3M 
Pi compared to experiments utilizing isotonic solutions.  An increase in mucus 
production is usually viewed as a protective mechanism to prevent damage to 
epithelium [252] and the manner in which this excess mucus and/or already damaged 
epithelium affects Pi transport is unknown.  Future studies may involve direct 
visualization of the epithelium following exposure to a high osmolarity buffer utilizing 
immunohistochemistry or electron microscopy.     
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Human studies have shown that a Pi load presented to the jejunum increases blood 
levels of Pi regulatory factors such as PTH without affecting other factors thought to be 
upstream of this sensing pathway (i.e. calcium levels) [258].  Other studies in CKD 
patients have shown that in contrast to the well documented association between FGF-
23 and dietary Pi intake [142], acute non-dietary modification of serum Pi levels (i.e. via 
dialysis) within the normal range does not induce changes plasma levels of FGF-23 
[143, 144].  Thus, it appears that intestinal Pi load and/or sensing may have the 
capability of regulating secretion of FGF-23 and PTH, which in turn would directly affect 
Pi reabsorption at the kidney.  Most recently, a group investigated the time of onset of 
phosphaturia following IV and duodenal Pi loading in humans [266].  Results show that 
there was no difference in onset of phosphaturia following IV and duodenal Pi loads, 
and both plasma Pi and PTH were elevated before any increase in FEPi.  This study 
furthers the evidence that the previously reported, acute gasto-renal Pi signaling does 
not exist.  With the knowledge that dietary Pi intervention and treatment with oral Pi 
binders have poor patient compliancy in CKD, an understanding of Pi sensing in the 
intestine is likely to be useful for new potential targets of treatment for 
hyperphosphataemia.  
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6.5 Liver and Pi handling 
 
The idea that the liver may release a factor which influences Pi homeostasis relates 
back to observations of clinical cases involving acute hypophosphatemia in patients 
following hepatectomy [149].  This phenomenon has been attributed to a marked 
increase in phosphaturia which occurred independently of the major known players of Pi 
homeostasis (PTH and phosphatonins) [150].  The underlying mechanism and cause for 
this phosphaturia remains unidentified.  
 
The results from experiments shown in Chapter 5 confirm that the liver accumulates 
more Pi when higher concentrations of Pi are instilled into the intestine; this pattern 
parallels the Pi transport mechanisms observed in the intestine.  One main different 
between Pi uptake by the liver and the intestine is that liver Pi accumulation plateaus 
between 10mM and 15mM Pi instillation into the intestine and may signify a saturation 
point for Pi transport into hepatocytes.  The normal range of intestinal luminal Pi 
concentration is approximately 0.7-12mM depending on the timing and composition of 
food [119], thus 15mM may exceed this physiological maximum.  The liver Pi uptake 
plateau revolving around this physiological maximum suggests that there is a Pi 
secretory function for the liver at supraphysiological Pi concentrations, potentially to 
protect the body from excess Pi by secreting it back into the bile to be recirculated into 
the small intestine in an analogous fashion to waste products, i.e. bilirubin. The 
utilization of higher concentrations of Pi to investigate this apparently saturable liver Pi 
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transport process was not furthered since these levels of Pi would not be considered 
physiologically relevant.  
 
The sodium dependency of Pi accumulation by the liver was investigated by substituting 
ChCl for NaCl in the buffer instilled into the jejunum.  Results show a differing pattern in 
sodium-dependent Pi uptake between the intestine and the liver.  Sodium-dependent Pi 
transport was seen following a jejunal Pi load at all four concentrations of Pi used (1, 5, 
10, and 15mM).  For the liver however, there was no sodium dependency seen until 
15mM Pi was instilled into the jejunum.  At this concentration, which is at the level of a 
supraphysiological Pi load, different mechanisms of Pi uptake are apparent.  This 
possibly suggests that the sodium phosphate cotransporters expressed in the liver may 
only be responsible for a small component of Pi transport at physiological levels and/or 
could be a part of a greater network of Pi handling that is still yet to be discovered.  The 
fact that no sodium-dependency was seen in liver Pi uptake prior to 15mM may not also 
rule out the function of sodium phosphate cotransporters in the liver, as the sodium-free 
buffer used as a jejunal Pi load would not be completely sodium-free upon arrival to the 
liver via the Na-plenty circulatory system.  Exsanguinations were also performed 
following Pi transport experiments to confirm that the Pi measured was contained in 
hepatic cells and not present in the blood vasculature of the liver.  
 
Future studies focusing on the role of the liver in Pi transport should include 
measurements of Pi levels in the bile.  Secreted bile serves to transport endogenous 
and exogenous waste for excretion and thus could potentially remove postprandial 
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excess levels of Pi that are sensed by the liver following uptake across the small 
intestine.  The knowledge that PiT1 and PiT2 transporters are expressed in 
cholangiocytes of the bile duct also provides grounds for investigating the role of bile in 
Pi transport.  Further studies could involve cannulation of the bile duct and observing 
whether changes in Pi concentrations occur in the bile following intestinal instillation of 
high concentrations of Pi (>15mM) and whether inhibition of this process of biliary Pi 
uptake leads to a dysregulation of body Pi homeostasis.   
 
A reported portal factor which was shown to regulate whole body calcium [264] could be 
similar to the unknown factor that is playing a role in Pi regulation.  Using experiments 
similar to the ones conducted in this thesis, this group observed plasma calcium levels 
in portacaval shunted Lewis rats following parathyroidectomy.  The results showed that 
there was correction of hypocalcemia in shunted mice which was independent of PTH, 
and the group proposed that a substance originated in the portal region which bypassed 
modifications in the liver.  This unaltered factor was then able to correct for the 
hypocalcemia following parathyroidectomy [264].  The clinically observed 
hypophosphatemia seen in hepatectomy could result from a factor with similar 
properties, since hepatectomy could temporarily disturb the liver’s modification abilities.  
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6.6. Overall conclusions 
 
Data obtained utilizing in vitro and in situ techniques confirm that the jejunum is the 
intestinal region with dominant Pi transport capacity and that there is a significant 
sodium-dependent Pi transport pathway in the jejunum, likely dependent on NaPi-IIb, 
which is highly expressed in this region.  A significant Pi transport ability in the distal 
colon is also evident from current studies and there has been no previous evidence of 
considerable Pi transport in this region of the intestine.  It can be concluded that for the 
study of Pi transport in regions of the small intestine where chyme only remains for a 
short period of time, the everted sleeve method may be a more accurate representative 
of physiological mechanisms taking place in vivo.  Studying intestinal regions where 
food remains for a longer period of time (distal small intestine/large intestine) may 
warrant other methods such as the in situ closed-loop technique.  Utilizing an ex vivo 
perfusion technique never previously used to investigate Pi transport, a concentration of 
Pi occurred in serosal fluid compared to perfusate buffer.  This concentration of Pi in the 
serosal fluid appears to be sodium-dependent since replacing normal perfusate buffer 
with one which was absent of sodium resulted in a significant decrease in Pi transport.  
The acute, gastro-renal signalling axis of Pi regulation proposed by Berndt et al [139, 
140] was also refuted following identical clearance surgeries in which a physiological Pi 
concentration (10mM) was instilled into the duodenum of rats.  A supraphysiological Pi 
concentration (1.3M), as used by Berndt et al [140] was also given to rats; data from 
these experiments showed an increase in serum Pi and plasma PTH.   These changes 
in plasma composition could explain the phosphaturia seen in some animals during 
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these experiments.  Lastly, the liver was shown to posses Pi transport properties by 
measuring the amount of Pi taken up by the liver following administration of Pi buffer 
into a closed-loop of intestine.  The concentration of Pi in the liver stabilised at luminal 
Pi levels of between 10 and 15mM, which is the range of Pi concentration present in the 
intestinal lumen.  Thus, the liver may play a regulatory role in Pi release into the 
systemic circulation following absorption across the small intestine (summary, Figure 
6.1).   
  
 
 
Figure 6.1. Summary of data and potential Pi signalling pathways between the small intestine, kidney, and the liver
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